Patent Application
20230203177
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 16, 2021, is named 200896_0016_WO-_SL.txt and is 281,538 bytes in size.
The disclosure provides variants of an antibody wherein the variant antibodies have improved pharmacokinetic properties relative to the corresponding unmodified antibody. In some cases, the antibody polypeptides bind CD40 and do not exhibit CD40 agonist activity. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
Biotherapeutic molecules are often the subject of modification experiments with the intent of trying to increase therapeutic effect, disease exposure, and/or safety profile. For antibody therapeutic molecules, modifications may include humanization, PEGylation, glycosylation, and conjugation to molecules such as albumin
Pharmacokinetics (PK) refers to the movement of a drug into, through, and out of the body. Drug pharmacokinetics assesses the onset, duration, and intensity of a drug's effect.
Pharmacokinetics of an antibody therapeutic can be influenced by a wide range of properties, including molecular size, folding stability, solubility, target interaction, neonatal Fc binding capacity, and charge (see, e.g., Warnders et al., 2018, Med. Res. Rev. 38: 1837-1873; Leipold and Prabhu, 2019, Clin. Transl. Sci. 12: 130-139). Charge modification of an antibody may influence charge-dependent interactions. For instance, increasing the basic/positive charge on a protein (cationization) can increase off-target interaction with membranes and extracellular matrix and tends to reduce pharmacokinetics, whereas anionization of a protein that has basic charge patches generally improves PK. However, protein modification to intentionally modulate in vivo behavior can also result in unintentional and undesirable effects due to the interdependence of many of the properties of proteins. Thus, pursuing charge modification of an antibody to modulate PK is not straightforward and requires intelligent protein design/engineering, and experimentation to find those mutations that work.
CD40 is a co-stimulatory molecule belonging to the tumor necrosis factor (TNF) receptor superfamily that is present on antigen presenting cells (APC), including dendritic cells, B cells, and macrophages. APCs are activated when CD40 binds its ligand, CD154 (CD40L), on Tx cells. CD40-mediated APC activation is involved in a variety of immune responses, including cytokine production, up-regulation of co-stimulatory molecules (such as CD86), and enhanced antigen presentation and B cell proliferation. CD40 can also be expressed by endothelial cells, smooth muscle cells, fibroblasts, and epithelial cells.
CD40 activation is also involved in a variety of undesired T cell responses related to autoimmunity, transplant rejection, or allergic responses, for example. One strategy for controlling undesirable T cell responses is to target CD40 with an antagonistic antibody, leading to the development of several monoclonal anti-CD40 antibodies, such as monoclonal antibody HCD122 (Lucatumumab), formerly known as Chiron 1212, fully human domain antibody BMS-986090 (U.S. Pat. No. 9,475,879). See also, e.g., WO 2018/217976 and WO 2018/217988.
The disclosure provides variants of an antibody wherein the variant antibodies have improved pharmacokinetic properties relative to the corresponding unmodified antibody. A method for increasing at least one pharmacokinetic property is also provided. The disclosure further provides anti-CD40 monoclonal antibody variants having similar or improved pharmacokinetic properties relative to the corresponding non-modified parent antibody. The disclosure also provides a method for the intelligent design of antibody variants having similar or improved pharmacokinetics relative to a corresponding non-modified antibody.
An isolated antibody, or antigen binding portion thereof, is provided that specifically binds to human CD40, wherein the antibody comprises a first polypeptide portion comprising a heavy chain variable region (VII), and a second polypeptide portion comprising a light chain variable region (VL), wherein the heavy chain variable region and the light chain variable region are selected from:
(i) said heavy chain variable region comprises HC1
LL
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTP
WTFGGGTKVEIK; SEQ ID NO. 41);
(ii) said heavy chain variable region comprises HC1
LL
WTFGGGTKVEIK; SEQ ID NO. 42);
(iii) said heavy chain variable region comprises HC15
VTITADKSTSTAYMELSSLRSEDTAVYY
LL
WTFGGGTKVEIK; SEQ ID NO. 42);
(iv) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEW
WTFGGGTKVEIK; SEQ ID NO. 45);
(v) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGL
YSTPWTFGGGTKVEIK; SEQ ID NO. 42);
or
(vi) said heavy chain variable region comprises HC5
PGSSVKVSC
ASGYAFTSYWMHWVRQAPGQGL
FSGSGSGTDFTLTISSLQPEDFATYYCQQH
YSTPWTFGGGTKVEIK; SEQ ID NO. 41).
The isolated antibody or antigen binding portion thereof can comprise the first polypeptide portion comprising a human heavy chain constant region; and the second polypeptide portion comprising a human light chain constant region. The isolated antibody or antigen binding portion thereof described herein can comprise a human IgG1 Fc domain comprising either (1) a mutation at Kabat position 238 that reduces binding to Fc-gamma-receptors (FcγRs), wherein proline 238 (P238) is mutated to one of the residues selected from the group consisting of lysine, serine, alanine, arginine, and tryptophan, and wherein the antibody or antigen binding portion thereof has reduced FcγR binding; or (2) an alanine substituted at Kabat position 297.
In some embodiments of the isolated antibody or antigen binding portion thereof described herein, the first polypeptide portion comprises a heavy chain variable region and a heavy chain constant region, and the second polypeptide portion comprises a light chain variable region and a light chain constant region wherein:
(i) said heavy chain variable region comprises HC1
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV; SEQ ID NO. 47);
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCQQH
YSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA
DYEKHKVYACEVTHQGLSSPVTKSFNRGEC; SEQ ID NO. 20);
(ii) said heavy chain variable region comprises HC1
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV; SEQ ID NO. 47);
YSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA
DYEKHKVYACEVTHQGLSSPNTKSFNRGEC; SEQ ID NO. 19);
(iii) said heavy chain variable region comprises HC15
VTITADKSTSTAYMELSSLRSEDT
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVT; SEQ ID NO. 48);
YSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA
DYEKHKVYACEVTHQGLSSPNTKSFNRGEC; SEQ ID NO. 19);
(iv) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGL
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV; SEQ ID NO. 49);
YSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA
DYEKHKVYACEVTHQGLSSPVTKSFNRGEC; SEQ ID NO. 17);
(v) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGL
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV; SEQ ID NO. 49);
YSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA
DYEKHKVYACEVTHQGLSSPNTKSFNRGEC; SEQ ID NO. 19);
or
(vi) said heavy chain variable region comprises HC5
PGSSVKVSC
ASGYAFTSYWMHWVRQAPGQGL
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV; SEQ ID NO. 50);
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCQQH
YSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA
DYEKHKVYACEVTHQGLSSPVTKSFNRGEC; SEQ ID NO. 20).
The isolated antibody or antigen binding portion thereof described herein can comprise a human IgG1 Fc domain comprising a mutation at Kabat position 238 that reduces binding to Fc-gamma-receptors (FcγRs), wherein proline 238 (P238) is mutated to one of the residues selected from the group consisting of lysine, serine, alanine, arginine, and tryptophan, and wherein the antibody or antigen binding portion has reduced FcγR binding. An exemplary antibody may have P238 mutated to lysine.
The isolated antibody or antigen binding portion thereof described herein can comprise an Fc domain which comprises an amino acid sequence selected from:
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG
VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV
The isolated antibody or antigen binding portion thereof can comprise a human IgG1 Fc domain comprising the amino acid sequence of SEQ ID NO: 22 or SEQ ID NO: 23.
An isolated antibody or antigen binding portion thereof described herein may comprise a human IgG1 Fc domain comprises a human IgG1 Fc domain comprising an alanine substituted at Kabat position 297.
An isolated antibody or antigen binding portion thereof as described herein can antagonize activities of CD40. The isolated antibody or antigen binding portion thereof described herein can be a chimeric antibody. The isolated antibody or antigen binding portion thereof described herein can be a humanized antibody. The isolated antibody or antigen binding portion thereof described herein can comprise a human heavy chain constant region and a human light chain constant region.
The antibody or antigen binding portion thereof disclosed herein may comprise an antigen binding portion selected from the group consisting of Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2, diabodies, and scFv-Fc. An exemplary isolated antibody or antigen binding portion thereof as described herein is a scFv-Fc.
The antibody or antigen binding portion thereof disclosed herein can linked to a therapeutic agent.
The antibody or antigen binding portion thereof disclosed herein can be linked to a second functional moiety having a different binding specificity than said antibody or antigen binding portion thereof.
The antibody or antigen binding portion thereof disclosed herein can further comprise an additional moiety.
A nucleic acid molecule encoding an isolated antibody or antigen binding portion thereof is disclosed herein. An expression vector comprising the nucleic acid molecule is disclosed herein. Also disclosed is a cell transformed with the expression vector that can express an isolated antibody or antigen binding portion thereof as disclosed herein. Also disclosed is a method of preparing an anti-human CD40 antibody, or antigen binding portion thereof, comprising:
a) expressing the antibody, or antigen binding portion thereof, in the cell transformed with the expression vector comprising the nucleic acid molecule encoding an isolated antibody or antigen binding portion thereof disclosed herein; and
b) isolating the antibody, or antigen binding portion thereof, from the cell.
Also provided is a pharmaceutical composition comprising: a) the antibody, or antigen binding portion thereof disclosed herein; and b) a pharmaceutically acceptable carrier.
A method is provided of treating or preventing an immune response in a subject comprising administering to the subject the antibody, or the antigen binding portion thereof, disclosed herein. Further provided is a method of treating or preventing an autoimmune or inflammatory disease in a subject, comprising administering to the subject the antibody, or the antigen binding portion, disclosed herein. Optionally, the antibody, or the antigen binding portion thereof, can be administered with an immunosuppressive/immunomodulatory and/or anti-inflammatory agent. Administration may be simultaneous or sequential. An exemplary agent for co-administration is a CTLA4 mutant molecule, such as L104EA29Y-Ig (belatacept).
In such method of treating or preventing an immune response in the subject, and in such method of treating or preventing an autoimmune or inflammatory disease in a subject, preferably the subject has a disease selected from the group consisting of: Addison's disease, allergies, anaphylaxis, ankylosing spondylitis, asthma, atherosclerosis, atopic allergy, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, autoimmune parotitis, bronchial asthma, coronary heart disease, Crohn's disease, diabetes, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel disease, immune response to recombinant drug products (e.g., Factor VII in hemophiliacs), lupus nephritis, lupus nephritis, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathies, thyroiditis, transplant rejection, vasculitis, and ulcerative colitis.
Also contemplated is an antibody, or antigen binding portion thereof as disclosed here, for use as a medicament. Further contemplated is an antibody, or antigen binding portion thereof as disclosed here, or a medicament comprising the same, for use to treat a subject in need thereof. Further contemplated is an antibody, or antigen binding portion thereof as disclosed herein in a therapeutically-effective amount, for use in treating or preventing an immune response, wherein the antibody or antigen binding portion thereof is for administering to a patient in need thereof.
The disclosure provides variants of an antibody wherein the variant antibodies have improved pharmacokinetic properties relative to the corresponding unmodified antibody. As shown here, it has been found that the specific site or location of a mutation to modify a surface charge patches is critical to improving antibody PK. This finding is unexpected as the prior art suggested that simply modifying the total antibody charge was needed to effect PK modification. Advantageously, in some instances, variants with only one or two strategically positions mutations with a small change in overall charge e.g., −2 or −3, have equivalent or improved PK compared to variants have multiple mutations and a larger charge change e.g. −8.
The disclosure further provides variants of antibodies that bind CD40 wherein the variants antibodies have improved pharmacokinetic properties relative to the corresponding unmodified antibody. The antibody polypeptides bind CD40 and do not exhibit CD40 agonist activity. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
The variant antibodies of the disclosure were identified by the method described in Example 1.
Further abbreviations and definitions are provided below.
APC antigen presenting cells
AUC area under the curve
BSA bovine serum album
CD54 also referred to as ICAM-1
CDR complementarity determining regions
CH or CH constant heavy chain
CL or CL constant light chain
CHO cell Chinese hamster ovary cell
DC dendritic cell
FcgR interchangeable with FcγR
FcγR Fc-gamma-receptor
FR Framework region
GM-CSF granulocyte macrophage colony stimulating factor
HC heavy chain
ICAM-1 intracellular adhesion molecule 1
iDC immature dendritic cells
IFN interferon
IgG immunoglobulin G
IL-6 interleukin-6
LC light chain
mAb monoclonal antibody
mg milligram
ml or mL milliliter
ng nanogram
nM nanomolar
pI isoelectric point
SPR surface plasmon resonance
TNF tumor necrosis factor
μg microgram
μM micromolar
VL or VL or Vl variable light chain domain
Vκ or Vk or VK kappa variable light chain domain
Vλ lambda variable light chain domain
VH or VH or Vh variable heavy chain domain
In accordance with this detailed description, the following abbreviations and definitions apply. It must be noted that as used herein, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an antibody” includes a plurality of such antibodies and reference to “the dosage” includes reference to one or more dosages and equivalents thereof known to those skilled in the art, and so forth.
As used here, the term “about” is understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. Generally, “about” encompasses a range of values that are plus/minus 10% of a referenced value unless indicated otherwise in the specification.
It is understood that any and all whole or partial integers between the ranges set forth are included herein.
CD40 is also known and referred to as B-cell surface antigen CD40, Bp50, CD40L receptor, CDw40, CDW40, MGC9013, p50, TNFRSF5, and tumor necrosis factor (TNF) receptor superfamily member 5. “Human CD40” refers to the CD40 comprising the following amino acid sequence:
As used herein, the term “variable domain” refers to immunoglobulin variable domains defined by Kabat et al., Sequences of Immunological Interest, 5th ed., U.S. Dept. Health & Human Services, Washington, D.C. (1991). The numbering and positioning of CDR amino acid residues within the variable domains is in accordance with the well-known Kabat numbering convention. VH, “variable heavy chain” and “variable heavy chain domain” refer to the variable domain of a heavy chain. VL, “variable light chain” and “variable light chain domain” refer to the variable domain of a light chain.
The term “human,” when applied to antibodies, means that the antibody has a sequence, e.g., FR and/or CH domains, derived from a human immunoglobulin. A sequence is “derived from” a human immunoglobulin coding sequence when the sequence is either: (a) isolated from a human individual or from a cell or cell line from a human individual; (b) isolated from a library of cloned human antibody gene sequences or of human antibody variable domain sequences; or (c) diversified by mutation and selection from one or more of the polypeptides above.
An “isolated” compound as used herein means that the compound is removed from at least one component with which the compound is naturally associated with in nature.
An antibody of the present disclosure, such as an anti-CD40 antibody, comprises a variable heavy chain and a variable light chain, each of which contains three complementarity-determining regions (CDRs) and four framework regions (FRs), arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The CDRs contain most of the residues that form specific interactions with the antigen and are primarily responsible for antigen recognition.
Pharmacokinetics (PK) refers to the movement of a drug into, through, and out of the body; PK assesses drug absorption, distribution, metabolism, and excretion of drugs from the body. Parameters for assessing pharmacokinetics include: AUC 0-inf (μM·h), T-half (h), MRT (h), CL (mL/h/kg) and Vss (L/kg).
PK parameters can be assessed by methods described herein.
As used herein, “improved pharmacokinetic properties” means that at least one PK parameter for an antibody variant is increased (for AUC, T-half and MRT) or decreased (for CL and Vss) relative to the same PK parameter measured in the corresponding non-modified antibody. In embodiments, an antibody variant has improved pharmacokinetic properties in at least two PK parameters, at least three PK parameters, at least four PK parameters, or at least five PK parameters relative to the same PK parameters in the corresponding non-modified antibody. As used herein, an improved pharmacokinetic property refers to a pharmacokinetic property of a variant antibody that is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or at least 100% greater than the same pharmacokinetic property of the corresponding unmodified antibody.
The exemplary anti-CD40 antibodies of the present disclosure are variants of humanized antibody BMS-986325 (also referred to as Y12XX-hz28). An overview of the amino acid sequences of the heavy chain variable region and light chain variable region of BMS-986325 is provided in Table 1.
Details of the amino acid sequences of BMS-986325 are provided in Table 2.
SYWMH
WVRQAPGQGLEWMGQINPTTGRSQY
NEKFKT
RVTITADKSTSTAYMELSSLRSED
SYWMH
WVRQAPGQGLEWMGQINPTTGRSQY
NEKFKT
RVTITADKSTSTAYMELSSLRSED
KGPSVFPLAPSSKSTSGGTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTK
VDKRVEPKSCDKTHTCPPCPAPELLGGKSV
SYWMH
WVRQAPGQGLEWMGQINPTTGRSQY
NEKFKT
RVTITADKSTSTAYMELSSLRSED
KGPSVFPLAPSSKSTSGGTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTK
VDKRVEPKSCDKTHTCPPCPAPELLGGKSV
TAVA
WYQQKPGKAPKLLIYSASYRYTGVPS
HYSTPWT
FGGGTKVEIK
TAVA
WYQQKPGKAPKLLIYSASYRYTGVPS
HYSTPWT
FGGGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKV
DNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFN
RGEC
The anti-CD40 variant antibodies of the present disclosure have at least one specific anionizing mutation in a variable domain relative to the corresponding framework region at least in BMS-986325. The anionizing mutations are of either Lysine (Lys; K) or Arginine (Arg; R) residues generally located in framework regions of the variable chains, and in some variants a CDR. Generally, specific lysine and arginine residues can be mutated to an uncharged residue, such as Glutamine (Gln; Q) or Asparagine (Asn; N), or a negatively charged (acidic) residue, such as Glutamate (Glu; E) or Aspartate (Asp; D). To avoid potential deamidation or isomerization, mutation to Gln and Glu are prioritized over mutation to Asn and Asp respectively to avoid potential deamidation (Asn) or isomerization (Asp) issues that are common for the shorter Asn and Asp side chains. The disclosed variants have improved PK related to BMS-986325.
Combinations of heavy chain variable region and light chain variable region sequences of variants of BMS-986325 disclosed herein are provided in Tables 3-8. These combinations each have a change in variable region net charge, relative to BMS-986325. Specifically, each combination has a decrease in net positive charge, except for those combinations including HC13. The variants bind human CD40 with a KD value similar to the KD for BMS-986325 or no more than about 4-fold higher (as measured by hCD40 binding to BMS-986325 and BMS-986325 variant antibodies captured out of supernatants).
Table 3 comprises combinations of various heavy chain variable region sequences with light chain variable region LC1.
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSCEASGYAFTSYWMHWVRQA
KPGSSVSVSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
QA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITAD
STSTAY
STSTAY
Table 4 comprises combinations of various heavy chain variable region sequences with light chain variable region LC2.
LC-K45Q
PGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSCQASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSCEASGYAFTSYWMHWVRQA
KPGSSVSVSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
QA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITAD
STSTAY
STSTAY
WMGQINPTTGRSQYN
KFKTRVTITADKSTSTAY
Table 5 comprises combinations of various heavy chain variable region sequences with light chain variable region LC3.
LC-K45E
LLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQP
PGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSCQASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
QPGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVSVSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITAD
STSTAY
STSTAY
WMGQINPTTGRSQYN
KFKTRVTITADKSTSTAY
Table 6 comprises combinations of various heavy chain variable region sequences with light chain variable region LC4.
LLIYSASY
YTGVPS
FSGSGSGTDFTLTISSLQP
PGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSCQASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
QPGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSV
VSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
QA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITADQSTSTAY
STSTAY
WMGQINPTTGRSQYN
KFKTRVTITADKSTSTAY
Table 7 comprises combinations of various heavy chain variable region sequences with light chain variable region LC5.
FSGSGSGTDFTLTISSLQP
PGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVSVSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
QA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITAD
STSTAY
STSTAY
WMGQINPTTGRSQYN
KFKTRVTITADKSTSTAY
Table 8 comprises combinations of various heavy chain variable region sequences with light chain variable region LC6.
PGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVSVSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
QA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITAD
STSTAY
STAY
WMGQINPTTGRSQYN
KFKTRVTITADKSTSTAY
Heavy chain variable region and light chain variable region sequences of exemplary variants of BMS-986325 having improved PK are provided in Table 9.
WMHWVRQAPGQGLEWMGQINPTTGRSQYNE
AWYQQKPGKAP LLIYSASY
YTGVPS
FSGS
KFKTRVTITADKSTSTAYMELSSLRSEDTAVYY
WMHWVRQAPGQGLEWMGQINPTTGRSQYNE
AWYQQKPGKAP LLIYSASYRYTGVPSRFSGSG
KFKTRVTITADKSTSTAYMELSSLRSEDTAVYY
WMHWVRQAPGQGLEWMGQINPTTGRSQYNE
AWYQQKPGKAP LLIYSASYRYTGVPSRFSGSG
KFKT VTITADKSTSTAYMELSSLRSEDTAVYY
WMHWVRQAPGQGLEWMGQINPTTGRSQYNE
AWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSG
KFKTRVIIADKSISAYMELSSLRSEDTAVYY
FGG
KPGSSVKVSCKASGYAFTSY
WMHWVRQAPGQGLEWMGQINPTTGRSQYNE
AWYQQKPGKAP LLIYSASYRYTGVPSRFSGSG
KFKTRVTITADKSTSTAYMELSSLRSEDTAVYY
PGSSVKVSC
ASGYAFTSY
WMHWVRQAPGQGLEWMGQINPTTGRSQYNE
AWYQQKPGKAP LLIYSASY
YTGVPS
FSGS
KFKTRVTITADKSTSTAYMELSSLRSEDTAVYY
Exemplary CD40 antibodies of the present disclosure can include an isolated antibody, or antigen binding portion thereof, that specifically binds to human CD40, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein:
(i) said heavy chain variable region comprises HC1
QINPTTGRSQYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCARW
GLQPFAYWGQGTLVTVSS; SEQ ID NO. 40);
LLI
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPW
TFGGGTKVEIK: SEQ ID NO. 41);
(ii) said heavy chain variable region comprises HC1
QINPTTGRSQYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCARW
GLQPFAYWGQGTLVTVSS; SEQ ID NO. 40);
ELL
(iii) said heavy chain variable region comprises HC15
QINPTTGRSQYNEKFKT
VTITADKSTSTAYMELSSLRSEDTAVYYCAR
WGLQPFAYWGQGTLVTVSS; SEQ ID NO. 43);
LLI
(iv) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEWM
WGLQPFAYWGQGTLVTVSS; SEQ ID NO. 44);
SASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFG
(v) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEWM
WGLQPFAYWGQGTLVTVSS; SEQ ID NO. 44);
LLI
or
(vi) said heavy chain variable region comprises HC5
PGSSVKVSC
ASGYAFTSYWMHWVRQAPGQGLEW
GLQPFAYWGQGTLVTVSS; SEQ ID NO. 46);
LLI
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTP
WTFGGGTKVEIK: SEQ ID NO. 41).
Exemplary CD40 antibodies of the present disclosure can include an isolated antibody, or antigen binding portion thereof, that specifically binds to human CD40, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein:
(i) said heavy chain variable region comprises HC1
QINPTTGRSQYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCARW
GLQPFAYWGQGTLVTVSS; SEQ ID NO. 40);
LLI
or
(ii) said heavy chain variable region comprises HC15 (QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEWMGQINPT TGRSQYNEKFKTVTITADKSTSTAYMELSSLRSEDTAVYYCARWGLQPFAYWGQG TLVTVSS; SEQ ID NO. 43); and said light chain variable region comprises LC3 (DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAP
LLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK; SEQ ID NO. 42). These two exemplary antibodies have the fewest mutations while also have a particularly advantageous combination of properties, including at least one improved PK parameter.
An “antibody” (Ab) shall include, without limitation, an immunoglobulin that binds specifically to an antigen and comprises at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, or an antigen-binding portion thereof. Each H chain comprises a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region comprises three constant domains, CH1, CH2 and CH3. Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region comprises one constant domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL comprises three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
An “antigen binding portion” of an Ab (also called an “antigen-binding fragment”) or antigen binding portion thereof refers to one or more sequences of an Ab (full length or fragment of the full length antibody) that retain the ability to bind specifically to the antigen bound by the whole Ab. Examples of an antigen-binding fragment include Fab, F(ab′)2, scFv (single-chain variable fragment), Fab′, dsFv, sc(Fv)2, and scFv-Fc.
A “humanized” antibody refers to an Ab in which some, most or all of the amino acids outside the CDR domains of a non-human Ab are replaced with corresponding amino acids derived from human immunoglobulins. In one embodiment of a humanized form of an Ab, some, most or all of the amino acids outside the CDR domains have been replaced with amino acids from human immunoglobulins, whereas some, most or all amino acids within one or more CDR regions are unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permissible as long as they do not abrogate the ability of the Ab to bind to a particular antigen. A “humanized” Ab retains an antigenic specificity similar to that of the original Ab.
A “chimeric antibody” refers to an Ab in which the variable regions are derived from one species and the constant regions are derived from another species, such as an Ab in which the variable regions are derived from a mouse Ab and the constant regions are derived from a human Ab.
As used herein, “specific binding” refers to the binding of an antigen by an antibody with a dissociation constant (Kd) of about 1 μM or lower as measured, for example, by surface plasmon resonance (SPR). Suitable assay systems include the BIAcore™ (GE Healthcare Life Sciences, Marlborough, Mass.) surface plasmon resonance system and BIAcore™ kinetic evaluation software (e.g., version 2.1).
Binding of the present antibodies to CD40 antagonizes at least one CD40 activity. “CD40 activities” include, but are not limited to, T cell activation (e.g., induction of T cell proliferation or cytokine secretion), macrophage activation (e.g., the induction of reactive oxygen species and nitric oxide in the macrophage), and B cell activation (e.g., B cell proliferation, antibody isotype switching, or differentiation to plasma cells). CD40 activities can be mediated by interaction with other molecules. “CD40 activities” include the functional interaction between CD40 and the following molecules, which are identified by their Uniprot Accession Number is parentheses:
CALR (P27797);
FBL (P22087);
POLR2H (P52434);
RFC5 (P40937);
SGK1 (000141);
SLC30A7 (Q8NEW0);
SLC39A7 (Q92504);
TRAF2 (Q5T1L5);
TRAF3 (Q13114);
TRAF6 (Q9Y4K3);
TXN (Q5T937);
UGGT1 (Q9NYU2); and
USP15 (Q9Y4E8).
For example, a CD40 “activity” includes an interaction with TRAF2. CD40/TRAF2 interaction activates NF-κB and JNK. See Davies et al., Mol. Cell Biol. 25: 9806-19 (2005). This CD40 activity thus can be determined by CD40-dependent cellular NF-κB and JNK activation, relative to a reference.
As used herein, the terms “activate,” “activates,” and “activated” refer to an increase in a given measurable CD40 activity by at least 10% relative to a reference, for example, at least 10%, 25%, 50%, 75%, or even 100%, or more. A CD40 activity is “antagonized” if the CD40 activity is reduced by at least 10%, and in an exemplary embodiment, at least about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, or even 100% (i.e., no detectable activity), relative to the absence of the antagonist. For example, an antibody may antagonize some or all CD40 activity, while not activating CD40. For example, the antibody may not activate B cell proliferation. The antibody may not activate cytokine secretion by T cells, where the cytokine is at least one cytokine selected from the group consisting of IL-2, IL-6, IL-10, IL-13, TNF-α, and IFN-γ.
The isolated antibody or antigen binding portion thereof can antagonize one or more activities of CD40. The isolated antibody or antigen binding portion thereof can be a chimeric antibody. The isolated antibody or antigen binding portion thereof can be a humanized antibody. The isolated antibody or antigen binding portion thereof can comprise a human heavy chain constant region and a human light chain constant region.
In certain aspects, the present disclosure describes variant framework regions (FR) and in some instances CDRs of the variable domains, wherein certain positions having a basic amino acid are mutated to a neutral or an acidic amino acid. The variant FRs disclosed may be variants of a framework region encoded by a human germline antibody gene segment such as a VH1 heavy chain germline and a VK1 light chain germline, or variants of modified FRs of a human germline antibody gene segment, for instance, variants arising from mutagenic affinity maturation of antibody libraries. Preferred framework sequences for use in the antibodies described herein are those that are structurally similar to the framework sequences used by anti-CD40 antibodies described herein. It is contemplated that VH CDR1, 2 and 3 sequences, and the VL CDR1, 2 and 3 sequences of any antibody can be grafted onto framework regions disclosed herein to improve one or more PK parameters. It is also contemplated that, as described herein, certain positions in CDRs that have a basic amino acid can also be modified.
Thus, the disclosure contemplates monoclonal antibody variants having similar or improved pharmacokinetic properties relative to the corresponding non-modified parent antibody. The parent antibody comprises a first polypeptide portion comprising a heavy chain variable region, said heavy chain variable region having the amino acid sequence QVQLVQSGAEVKKPGSSVKVSCKASGYAFTXXXXXWVRQAPGQGLEWMGXXXX XXXXXXXXXXXXXRVTITADKSTSTAYMELSSLRSEDTAVYYCARXXXXXXXXW GQGTLVTVSS (SEQ ID NO: 73); and a second polypeptide portion comprising a light chain variable region, said light chain variable region having the amino acid sequence DIQMTQSPSFLSASVGDRVTITCXXXXXXXXXXXWYQQKPGKAPKWYXXXXXX XGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCXXXXXXXXXFGGGTKVEIK. (SEQ ID NO: 74) or DIQMTQSPSFLSASVGDRVTITCXXXXXXXXXXXWYQQKPGKAPKWYXXXXXX XGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCXXXXXXXXXFGGGTKVEIKR (SEQ ID NO: 75) In SEQ ID NO: 75, position 108 is the first amino acid of the constant region (CL). Position 108 can be a basic amino acid, such as an arginine as shown in SEQ ID NO:
75.
The antibody variants comprise at least one anionizing mutation at a basic residue. The heavy chain variable region of the variant can comprise a mutation at at least one position having a basic residue in the parent antibody, the at least one position selected from the group consisting of 12, 13, 19, 23, 38, 57, 63, 67, and 74, and combinations thereof, of SEQ ID NO: 73. The heavy chain variable region of the variant can comprise at least one mutation as a position selected from the group consisting of K12, K13, K19, K23, R38, R57, K63, R67, and R74 and combinations thereof. The mutation can replace the basic amino acid with either a neutral amino acid or an acidic amino acid. Exemplary neutral amino acids include glutamine, asparagine, valine, serine, alanine, and threonine. Exemplary acid amino acids include glutamate and aspartate. Combinations of mutations can be made at two or more of positions 12, 13, 19, 23, 38, 57, 63, 67, and 74 of SEQ ID NO: 73. Examples include, but are not limited to, mutations at positions 12 and 13; mutations at positions 12, 13, and 23; mutations at positions 38, 63, and 67; mutations at positions 63 and 67; and mutations at positions 57 and 74. In some variant antibodies, examples of combinations include, but are not limited to, mutations at K12 and K13Q; mutations at K12, K13, and K23; mutations at R38, K63 and R67; mutations at K63 and R67; and mutations at R57 and K74. Exemplary combinations of mutations include K12Q, and K13Q; K12Q, K13Q, and K23Q; K12E, K13Q, and K23E; K12V, K19S, and K23A; R38Q, K63Q, and R67Q; K63Q and R67E; and R57E and K74Q.
The light chain variable region of the variant can comprise a mutation at at least one position having a basic residue in the parent antibody, the at least one position selected from the group consisting of 45, 54, 61, and 107, and combinations thereof, of SEQ ID NO: 74 or the at least one position selected from the group consisting of 45, 54, 61, 107, and 108, and combinations thereof, of SEQ ID NO: 75. The light chain variable region of the variant can comprise a mutation at at least one position selected from the group consisting of K45, R54, R61, K107 and if present, R108, and combinations thereof. The mutation can replace the basic amino acid with a neutral amino acid or an acidic amino acid. Exemplary neutral amino acids include glutamine (E), asparagine (N), valine (V), serine (S), alanine (A), and threonine (T). In some cases, the neutral amino acid is glutamine. Exemplary acidic amino acids include glutamate (E) and aspartate (E). In some cases, the acidic amino acid is glutamate. Combinations of mutations can be made at two or more of positions 45, 54, 61, and 107 of SEQ ID NO: 74, or 45, 54, 61, 107, and 108 of SEQ ID NO: 75. Examples include, but are not limited to, mutation at positions 45, 54, and 61; or mutation at positions 107 and 108. In some variant antibodies, examples of combinations include, but are not limited to, K45, R54 and R61; and K107 and K108. Exemplary combinations of mutations include K45Q, R54Q and R61Q; and K107Q and K108Q.
The disclosure further provides a method for improving at least one pharmacokinetic property of a parent antibody. The method comprises mutating a residue at at least one position selected from 12, 13, 19, 23, 38, 57, 63, 67, and 74 of SEQ ID NO: 73 and/or 45, 54, 61, and 107 of SEQ ID NO: 74 to produce a variant having at least one improved pharmacokinetic property, relative to the non-modified parent antibody. In some cases, the method comprises mutating a residue at at least one position selected from 12, 13, 19, 23, 38, 57, 63, 67, and 74 of SEQ ID NO: 73 and/or 45, 54, 61, 107, and 108 of SEQ ID NO: 75 to produce a variant having at least one improved pharmacokinetic property, relative to the non-modified parent antibody.
In practicing the method, the mutation can be to a neutral amino acid or to an acidic amino acid. Exemplary neutral amino acids include glutamine, asparagine, valine, serine, alanine, and threonine. Exemplary acid amino acids include glutamate and aspartate.
Combinations of mutations can be made at residues at two or more of positions 45, 54, 61, and 107, and combinations thereof, of SEQ ID NO: 74, or 45, 54, 61, 107, and 108, and combinations thereof, of SEQ ID NO: 75. Examples include, but are not limited to, mutation at positions 45, 54, and 61 of SEQ ID NO: 74; or mutations at 107 and 108 of SEQ ID NO: 75.
Combinations of mutations can be made at two or more positions 12, 13, 19, 23, 38, 57, 63, 67, and 74, and combinations thereof, of SEQ ID NO: 73. Examples include, but are not limited to, mutations at positions 12 and 13; positions 12, 13, and 23; positions 38, 63, and 67; positions 63 and 67, and positions 57 and 74.
The improved pharmacokinetic property obtained by the method can be area under the concentration-time curve from time 0 to infinity (AUC 0-inf (uM·h)), half-life (T-half (h)), mean residence time (MRT (h)), clearance (CL (mL/h/kg), and volume of distribution at steady state (Vss (L/kg)).
Exemplary combinations of variant framework regions are provided in Table 10.
XXXXXXXWYQQKPGKAP LLIYXXX
X
XXGVPS FSGSGSGTDFTLTISSLQP
XXXXXXXWYQQKPGKAP LLIYXXX
XXXXGVPSRFSGSGSGTDFTLTISSLQP
XXXXXXXWYQQKPGKAP LLIYXXX
VTITA
XXXXGVPSRFSGSGSGTDFTLTISSLQP
KPGSSVKVSCKAS
XXXXXXXWYQQKPGKAPKLLIYXXX
XXXXGVPSRFSGSGSGTDFTLTISSLQP
KPGSSVKVSCKAS
XXXXXXXWYQQKPGKAP LLIYXXX
XXXXGVPSRFSGSGSGTDFTLTISSLQP
PGSSVKVSC
AS
XXXXXXXWYQQKPGKAP LLIYXXX
X
XXGVPS FSGSGSGTDFTLTISSLQP
Antibodies contemplated in the present disclosure can include an isolated antibody, or antigen binding portion thereof, that specifically binds to an antigen, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein:
(i) said heavy chain variable region comprises the HC1 framework
XXXXXXXXXXXXXXXXXRVTITADKSTSTAYMELSSLRSEDTAVYYCARX
XXXXXXXWGQGTLVTVSS; SEQ ID NO. 73);
LLI
XXGVPS
QFSGSGSGTDFTLTISSLQPEDFATYYCXXXXXXX
XXFGGGTKVEIK: SEQ ID NO. 80);
(ii) said heavy chain variable region comprises the HC1 framework
XXXXXXXXXXXXXXXXXRVTITADKSTSTAYMELSSLRSEDTAVYYCARX
XXXXXXXWGQGTLVTVSS; SEQ ID NO. 73);
LLI
(iii) said heavy chain variable region comprises the HC15 framework
XXXXXXXXXXXXXXXXX
VTITADKSTSTAYMELSSLRSEDTAVYYCAR
XXXXXXXXWGQGTLVTVSS; SEQ ID NO. 76);
LLI
(iv) said heavy chain variable region comprises the HC4 framework
KPGSSVKVSCKASGYAFTXXXXXWVRQAPGQGLEWM
XXXXXXXXWGQGTLVTVSS; SEQ ID NO. 78);
XXXXXXXGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCXXXXXXXXXFG
(v) said heavy chain variable region comprises the HC4 framework
KPGSSVKVSCKASGYAFTXXXXXWVRQAPGQGLEWM
XXXXXXXXWGQGTLVTVSS; SEQ ID NO. 78);
LLI
or
(vi) said heavy chain variable region comprises the HC5 framework
PGSSVKVSC
ASGYAFTXXXXXWVRQAPGQGLEW
XXXXXXXXWGQGTLVTVSS; SEQ ID NO. 79);
LLI
XXGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCXXXXXXX
XXFGGGTKVEIK: SEQ ID NO. 80).
Antibodies contemplated in the present disclosure can include an isolated antibody, or antigen binding portion thereof, that specifically binds to an antigen, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein said heavy chain variable region comprises the HC1 framework
XXXXXXXXXXXXXXXXXRVTITADKSTSTAYMELSSLRSEDTAVYYCARX
XXXXXXXWGQGTLVTVSS; SEQ ID NO. 73);
LLIY
XXXXXXXGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCXXXXXXXXXFG
Antibodies contemplated in the present disclosure can include an isolated antibody, or antigen binding portion thereof, that specifically binds to an antigen, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein said heavy chain variable region comprises the HC15 framework
XXXXXXXXXXXXXXXXX
VTITADKSTSTAYMELSSLRSEDTAVYYCAR
XXXXXXXXWGQGTLVTVSS; SEQ ID NO. 76);
LLI
The carboxyl-terminal “half” of a heavy chain defines a constant region (Fc) and which is primarily responsible for effector function. As used herein, the term “Fc domain” refers to the constant region antibody sequences comprising CH2 and CH3 constant domains as delimited according to Kabat et al., Sequences of Immunological Interest, 5th ed., U.S. Dept. Health & Human Services, Washington, D.C. (1991). The Fc region may be derived from a human IgG. For instance, the Fc region may be derived from a human IgG1 or a human IgG4 Fc region. A heavy variable domain can be fused to an Fc domain The carboxyl terminus of the variable domain may be linked or fused to the amino terminus of the Fc CH2 domain. Alternatively, the carboxyl terminus of the variable domain may be linked or fused to the amino terminus of a linker amino acid sequence, which itself is fused to the amino terminus of an Fc domain. Alternatively, the carboxyl terminus of the variable domain may be linked or fused to the amino terminus of a CH1 domain, which itself is fused to the Fc CH2 domain. Optionally, the protein may comprise the hinge region after the CH1 domain in whole or in part. Optionally an amino acid linker sequence is present between the variable domain and the Fc domain. The carboxyl terminus of the light variable domain may be linked or fused to the amino terminus of a CL domain.
An exemplary sequence for a heavy chain CH1 is amino acids 118-215 of SEQ ID NO: 82
Exemplary heavy chain variable region and light chain variable region sequences of exemplary variants of BMS-986325 having improved PK are provided in Table 11. In these sequences, the heavy chain comprises an exemplary CH1 domain and the light chain comprises an exemplary CL domain.
DVSTAVAWYQQKPGKAP LLIYSASY
INPTTGRSQYNEKFKTRVTITADKSTST
YTGVPS
FSGSGSGTDFTLTISSLQPE
AYWGQGTLVTVSSASTKGPSVFPLAPS
RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
SKSTSGGTAALGCLVKDYFPEPVTVSWN
NFYPREAKVQWKVDNALQSGNSQESVTE
SGALTSGVHTFPAVLQSSGLYSLSSVVTV
QDSKDSTYSLSSTLTLSKADYEKHKVYAC
PSSSLGTQTYICNVNHKPSNTKVDKRV
EVTHQGLSSPVTKSFNRGEC
DVSTAVAWYQQKPGKAP LLIYSASY
INPTTGRSQYNEKFKTRVTITADKSTST
RYTGVPSRFSGSGSGTDFTLTISSLQPE
AYWGQGTLVTVSSASTKGPSVFPLAPS
RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
SKSTSGGTAALGCLVKDYFPEPVTVSWN
NFYPREAKVQWKVDNALQSGNSQESVTE
SGALTSGVHTFPAVLQSSGLYSLSSVVTV
QDSKDSTYSLSSTLTLSKADYEKHKVYAC
PSSSLGTQTYICNVNHKPSNTKVDKRV
EVTHQGLSSPVTKSFNRGEC
DVSTAVAWYQQKPGKAP LLIYSASY
INPTTGRSQYNEKFKT VTITADKSTS
RYTGVPSRFSGSGSGTDFTLTISSLQPE
FAYWGQGTLVTVSSASTKGPSVFPLAP
RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
SSKSTSGGTAALGCLVKDYFPEPVTVSW
NFYPREAKVQWKVDNALQSGNSQESVTE
NSGALTSGVHTFPAVLQSSGLYSLSSVVT
QDSKDSTYSLSSTLTLSKADYEKHKVYAC
VPSSSLGTQTYICNVNHKPSNTKVDKRV
EVTHQGLSSPVTKSFNRGEC
KPGSSVKVSCKASG
DVSTAVAWYQQKPGKAPKLLIYSASY
INPTTGRSQYNEKFKTRVTITADKSTST
RYTGVPSRFSGSGSGTDFTLTISSLQPE
FGGGTKVEIK
AYWGQGTLVTVSSASTKGPSVFPLAPS
RTVAAPSVFIFPPSDEQLKSGTASVNCLL
SKSTSGGTAALGCLVKDYFPEPVTVSWN
NNFYPREAKVQWKVDNALQSGNSQESVT
SGALTSGVHTFPAVLQSSGLYSLSSVVTV
EQDSKDSTYSLSSTLTLSKADYEKHKVYA
PSSSLGTQTYICNVNHKPSNTKVDKRV
CEVTHQGLSSPVTKSFNRGEC
KPGSSVKVSCKASG
DVSTAVAWYQQKPGKAP LLIYSASY
INPTTGRSQYNEKFKTRVTITADKSTST
RYTGVPSRFSGSGSGTDFTLTISSLQPE
AYWGQGTLVTVSSASTKGPSVFPLAPS
RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
SKSTSGGTAALGCLVKDYFPEPVTVSWN
NFYPREAKVQWKVDNALQSGNSQESVTE
SGALTSGVHTFPAVLQSSGLYSLSSVVTV
QDSKDSTYSLSSTLTLSKADYEKHKVYAC
PSSSLGTQTYICNVNHKPSNTKVDKRV
EVTHQGLSSPVTKSFNRGEC
PGSSVKVSC
ASG
DVSTAVAWYQQKPGKAP LLIYSASY
INPTTGRSQYNEKFKTRVTITADKSTST
YTGVPS
FSGSGSGTDFTLTISSLQPE
AYWGQGTLVTVSSASTKGPSVFPLAPS
RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
SKSTSGGTAALGCLVKDYFPEPVTVSWN
NFYPREAKVQWKVDNALQSGNSQESVTE
SGALTSGVHTFPAVLQSSGLYSLSSVVTV
QDSKDSTYSLSSTLTLSKADYEKHKVYAC
PSSSLGTQTYICNVNHKPSNTKVDKRV
EVTHQGLSSPVTKSFNRGEC
The antibody can be a fusion antibody comprising a first variable domain that specifically binds human CD40, and a second domain comprising an Fc domain
Exemplary Fc domains used in the fusion protein can include human IgG domains Exemplary human IgG Fc domains include IgG4 Fc domain and IgG1 Fc domain. While human IgG heavy chain genes encode a C-terminal lysine, the lysine is often absent from endogenous antibodies as a result of cleavage while in blood circulation. Antibodies having IgG heavy chains including a C-terminal lysine, when expressed in mammalian cell cultures, may also have variable levels of C-terminal lysine present (Cai et al, 2011, Biotechnol. Bioeng. 108(2): 404-12). Accordingly, the C-terminal lysine of any IgG heavy chain Fc domain disclosed herein may be omitted.
The isolated antibody or antigen binding portion thereof described herein, can comprise an Fc domain which comprises an amino acid sequence of: EPKSCDKTHTCPPCPAPELLGG(P/K)SVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY(N/A)STYRVVSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR(D/E) E(L/M)TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG(K/not present) (Fc consensus; SEQ ID NO: 87). The parenthetical notation indicates possible amino acid identities at the position. For instance, Kabat position 238 can be either Proline (P) or Lysine (K), which is notated as (P/K). Additional exemplary, non-limiting consensus sequences are SEQ ID NOs: 118-120:
The isolated antibody or antigen binding portion thereof described herein can comprise a human IgG1 Fc domain comprising a mutation at Kabat position 238 that reduces binding to Fc-gamma-receptors (FcγRs), wherein proline 238 (P238) is mutated to one of the residues selected from the group consisting of lysine (K), serine (S), alanine (A), arginine (R) and tryptophan (W), and wherein the antibody or antigen binding portion thereof has reduced FcγR binding. The isolated antibody or antigen binding portion thereof described herein can have P238 mutated to lysine in a human IgG1 Fc domain.
The isolated antibody or antigen binding portion thereof comprises an Fc domain which comprises an amino acid sequence selected from: SEQ ID NOs: 22-29.
Exemplary sequences comprising the IgG1 Fc domains above include the four different VH chain sequences set forth in Table 12.
The isolated antibody or antigen binding portion thereof described herein can comprise a human IgG1 Fc domain comprising an alanine substituted at Kabat position 297. For example, the isolated antibody or antigen binding portion thereof comprises an Fc domain which comprises an amino acid sequence selected from: SEQ ID NOs: 141-148.
Exemplary heavy chain variable region and light chain variable region sequences of exemplary variants of BMS-986325 having improved PK are provided in Table 12. In these sequences, the heavy chain comprises an exemplary CH1 domain and a human IgG1 C domain comprising a mutation at Kabat position 238 that reduces binding to Fc-gamma-receptors (FcγRs), wherein proline 238 (P238) is mutated to one of the residues selected from the group consisting of lysine (K). The light chain comprises an exemplary CL domain
DVSTAVAWYQQKPGKAP LLIYSASY
INPTTGRSQYNEKFKTRVTITADKSTST
YTGVPS FSGSGSGTDFTLTISSLQPE
AYWGQGTLVTVSSASTKGPSVFPLAPS
RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
SKSTSGGTAALGCLVKDYFPEPVTVSWN
NFYPREAKVQWKVDNALQSGNSQESVTE
SGALTSGVHTFPAVLQSSGLYSLSSVVTV
QDSKDSTYSLSSTLTLSKADYEKHKVYAC
PSSSLGTQTYICNVNHKPSNTKVDKRVEP
EVTHQGLSSPVTKSFNRGEC
DVSTAVAWYQQKPGKAP LLIYSASY
INPTTGRSQYNEKFKTRVTITADKSTST
RYTGVPSRFSGSGSGTDFTLTISSLQPE
AYWGQGTLVTVSSASTKGPSVFPLAPS
RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
SKSTSGGTAALGCLVKDYFPEPVTVSWN
NFYPREAKVQWKVDNALQSGNSQESVTE
SGALTSGVHTFPAVLQSSGLYSLSSVVTV
QDSKDSTYSLSSTLTLSKADYEKHKVYAC
PSSSLGTQTYICNVNHKPSNTKVDKRVEP
EVTHQGLSSPVTKSFNRGEC
DVSTAVAWYQQKPGKAP LLIYSASY
INPTTGRSQYNEKFKT
VTITADKSTS
RYTGVPSRFSGSGSGTDFTLTISSLQPE
FAYWGQGTLVTVSSASTKGPSVFPLAP
RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
SSKSTSGGTAALGCLVKDYFPEPVTVSW
NFYPREAKVQWKVDNALQSGNSQESVTE
NSGALTSGVHTFPAVLQSSGLYSLSSVVT
QDSKDSTYSLSSTLTLSKADYEKHKVYAC
VPSSSLGTQTYICNVNHKPSNTKVDKRVE
EVTHQGLSSPVTKSFNRGEC
KPGSSVKVSCKASG
DVSTAVAWYQQKPGKAPKLLIYSASY
INPTTGRSQYNEKFKTRVTITADKSTST
RYTGVPSRFSGSGSGTDFTLTISSLQPE
AYWGQGTLVTVSSASTKGPSVFPLAPS
RTVAAPSVFIFPPSDEQLKSGTASVVCLL
SKSTSGGTAALGCLVKDYFPEPVTVSWN
NNFYPREAKVQWKVDNALQSGNSQESVT
SGALTSGVHTFPAVLQSSGLYSLSSVVTV
EQDSKDSTYSLSSTLTLSKADYEKHKVYA
PSSSLGTQTYICNVNHKPSNTKVDKRVEP
CEVTHQGLSSPVTKSFNRGEC
KPGSSVKVSCKASG
DVSTAVAWYQQKPGKAP LLIYSASY
INPTTGRSQYNEKFKTRVTITADKSTST
RYTGVPSRFSGSGSGTDFTLTISSLQPE
AYWGQGTLVTVSSASTKGPSVFPLAPS
RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
SKSTSGGTAALGCLVKDYFPEPVTVSWN
NFYPREAKVQWKVDNALQSGNSQESVTE
SGALTSGVHTFPAVLQSSGLYSLSSVVTV
QDSKDSTYSLSSTLTLSKADYEKHKVYAC
PSSSLGTQTYICNVNHKPSNTKVDKRVEP
EVTHQGLSSPVTKSFNRGEC
PGSSVKVSC
ASG
DVSTAVAWYQQKPGKAP LLIYSASY
INPTTGRSQYNEKFKTRVTITADKSTST
YTGVPS FSGSGSGTDFTLTISSLQPE
AYMELSSLRSEDTAVYYCARWGLQPF
RTVAAPSVFIFPPSDEQLKSGTASVVCLLN
SKSTSGGTAALGCLVKDYFPEPVTVSWN
NFYPREAKVQWKVDNALQSGNSQESVTE
SGALTSGVHTFPAVLQSSGLYSLSSVVTV
QDSKDSTYSLSSTLTLSKADYEKHKVYAC
PSSSLGTQTYICNVNHKPSNTKVDKRVEP
EVTHQGLSSPVTKSFNRGEC
The antigen binding portion thereof of any antibody disclosed herein, can be selected from the group consisting of Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2, diabodies, and scFv-Fc.
The antibody or antigen binding portion thereof disclosed herein can be an immunoconjugate, wherein the antibody or antigen-binding portion thereof is linked to a therapeutic agent.
The antibody or antigen binding portion thereof disclosed herein can be a bispecific antibody, wherein the antibody or antigen-binding portion thereof is linked to a second functional moiety having a different binding specificity than said antibody or antigen binding portion thereof.
The antibody or antigen binding portion thereof disclosed herein can further comprise an additional moiety.
The variable regions of the present antibodies may optionally be linked to an Fc domain by an “amino acid linker” or “linker.” For example, the C-terminus of a variable heavy chain domain may be fused to the N-terminus of an amino acid linker, and an Fc domain may be fused to the C-terminus of the linker. Although amino acid linkers can be any length and consist of any combination of amino acids, the linker length may be relatively short (e.g., five or fewer amino acids) to reduce interactions between the linked domains. The amino acid composition of the linker also may be adjusted to reduce the number of amino acids with bulky side chains or amino acids likely to introduce secondary structure. Suitable amino acid linkers include, but are not limited to, those up to 3, 4, 5, 6, 7, 10, 15, 20, or 25 amino acids in length. Representative amino acid linker sequences include GGGGS (SEQ ID NO: 92), and a linker comprising 2, 3, 4, or 5 copies of GGGGS (SEQ ID NOs: 93 to 96, respectively). Table 13 lists suitable linker sequences for use in the present disclosure.
The antibody can be produced and purified using ordinary skill in a suitable mammalian host cell line, such as CHO, 293, COS, NSO, and the like, followed by purification using one or a combination of methods, including protein A affinity chromatography, ion exchange, reverse phase techniques, or the like.
As well known in the art, multiple codons can encode the same amino acid. Nucleic acids encoding a protein sequence thus include nucleic acids having codon degeneracy. The polypeptide sequences disclosed herein can be encoded by a variety of nucleic acids. The genetic code is universal and well known. Nucleic acids encoding any polypeptide sequence disclosed herein can be readily conceived based on conventional knowledge in the art as well as optimized for production. While the possible number of nucleic acid sequence encoding a given polypeptide is large, given a standard table of the genetic code, and aided by a computer, the ordinarily skilled artisan can easily generate every possible combination of nucleic acid sequences that encode a given polypeptide.
Representative nucleic acid sequences encoding four of the heavy chain variable domains are provided below. In these sequences, nucleotides 1-351 encode the heavy chain variable region in which nucleotides 91-105 encode CDR1, nucleotides 148-195 encode CDR2, and nucleotides 295-318_encode CDR3 of the variable domain of the heavy chain. Nucleotides 352-645 encode a CH1 domain, and nucleotides 646-1341_encode IgG1-P238K. Nucleotides 1342-1344_are a stop codon.
A representative nucleic acid sequence encoding the heavy chain variable domain (HC1 i.e., HC-wt) of M39 and M33 (CDRs are underlined) and including a constant region CH1 (italicized) and Fc domain IgG1-P238K is:
GATGCACTGGGTGAGACAGGCTCCTGGACAGGGCCTGGAGTGGATGGGC
CAGATCAACCCAACCACCGGCAGAAGCCAGTACAATGAGAAGTTTAAGA
TGGGGCCTGCAGCCTTTCGCTTACTGGGGCCAGGGCACCCTGGTGACAG
CAGCAAGTCTACCTCCGGAGGAACAGCCGCTCTGGGATGTCTGGTGAAG
GACTACTTCCCAGAGCCCGTGACAGTGTCCTGGAACAGCGGCGCCCTGA
CCTCCGGCGTGCATACATTTCCAGCTGTGCTGCAGTCTTCCGGCCTGTA
CAGCCTGAGCTCTGTGGTGACCGTGCCCTCCAGCTCTCTGGGCACCCAG
ACATATATCTGCAACGTGAATCACAAGCCATCCAATACAAAGGTGGACA
AGAGGGTGGAGCCCAAGAGCAGAGAAAAGACCCATACATGCCCACCTTG
A representative nucleic acid sequence encoding the heavy chain variable domain (HC-15) of M47 and including a constant region CH1 and Fc domain IgG1-P238K is:
A representative nucleic acid sequence encoding the heavy chain variable domain (HC-4) of M4 and M36 and including a constant region CH1 and Fc domain IgG1-P238K is:
A representative nucleic acid sequence encoding the heavy chain variable domain (HC-5) of M53 and including a constant region CH1 and Fc domain IgG1-P238K is:
Representative nucleic acid sequences encoding three of the light chain variable domains are provided below. In these sequences, nucleotides 1-321 encode the light chain variable region in which nucleotides 70-102 encode CDR1, nucleotides 148-168 encode CDR2, and nucleotides 265-291 encode CDR3. Nucleotides 322-642 encode a CL. Nucleotides 643-645 are a stop codon.
A representative nucleic acid sequence encoding the light chain variable domain (LC4) of M39 and M53 (CDRs are underlined) and including a constant region CL (italicized) is:
CTTGGTACCAGCAGAAGCCAGGCAAGGCCCCCCAGCTGCTGATCTATTCC
GCCTCTTACCAGTATACCGGAGTGCCATCCCAGTTCTCCGGCAGCGGCTC
CTTTCCCCCTTCTGACGAGCAGCTGAAGTCTGGCACAGCTTCCGTGGTGT
GCCTGCTGAACAATTTCTACCCTCGCGAGGCCAAGGTGCAGTGGAAGGTG
GATAACGCTCTGCAGTCCGGCAATAGCCAGGAGTCTGTGACCGAGCAGGA
CTCCAAGGATAGCACATATTCTCTGTCTTCCACCCTGACACTGTCCAAGG
CCGACTACGAGAAGCATAAGGTGTATGCTTGTGAAGTCACCCACCAGGGG
CTGAGTTCACCAGTCACAAAATCTTTCAATAGAGGGGAATGTTGA.
A representative nucleic acid sequence encoding the light chain variable domain (LC3) of M33, M47, and M36 and including a constant region CL is:
TCCGCCTCTTACAGGTATACCGGAGTGCCATCCCGGTTCTCCGGCAGCG
TGTTCATCTTTCCCCCTTCTGACGAGCAGCTGAAGTCTGGCACAGCTTC
CGTGGTGTGCCTGCTGAACAATTTCTACCCTCGCGAGGCCAAGGTGCAG
TGGAAGGTGGATAACGCTCTGCAGTCCGGCAATAGCCAGGAGTCTGTGA
CCGAGCAGGACTCCAAGGATAGCACATATTCTCTGTCTTCCACCCTGAC
ACTGTCCAAGGCCGACTACGAGAAGCATAAGGTGTATGCTTGTGAAGTC
ACCCACCAGGGGCTGAGTTCACCAGTCACAAAATCTTTCAATAGAGGGG
AATGTTGA.
A representative nucleic acid sequence encoding the light chain variable domain (LC1 i.e. LC-wt) of M4 and including a constant region CL is:
TGTTCATCTTTCCCCCTTCTGACGAGCAGCTGAAGTCTGGCACCGCTTC
CGTGGTGTGCCTGCTGAACAATTTCTACCCTCGGGAGGCCAAGGTGCAG
TGGAAGGTGGATAACGCTCTGCAGTCCGGCAATAGCCAGGAGTCTGTGA
CCGAGCAGGACTCCAAGGATAGCACATATTCTCTGTCTTCCACCCTGAC
ACTGTCCAAGGCCGATTACGAGAAGCACAAGGTGTATGCTTGCGAGGTG
ACCCATCAGGGCCTGAGCTCTCCCGTGACAAAGAGCTTTAACCGCGGCG
AGTGTTGA.
Exemplary coding sequences are summarized below in Table 14. The sequences are provided in the sequence listing.
The coding sequence for the heavy and/or light chain optionally may encode a signal peptide, such as MRAWIFFLLCLAGRALA (SEQ ID NO: 51), at the 5′ end of the coding sequence. An exemplary nucleic acid coding sequence for this signal peptide is
Accordingly, a nucleic acid encoding an antibody disclosed herein is also contemplated. Such a nucleic acid may be inserted into a vector, such as a suitable expression vector, e.g., pHEN-1 (Hoogenboom et al. (1991) Nucleic Acids Res. 19: 4133-4137). Further provided is an isolated host cell comprising the vector and/or the nucleic acid.
The antibody of the disclosure can be produced and purified using only ordinary skill in any suitable mammalian host cell line, such as CHO (Chinese hamster ovary cells), 293 (human embryonic kidney 293 cells), COS cells, NSO cells, and the like, followed by purification using one or a combination of methods, including protein A affinity chromatography, ion exchange, reverse phase techniques, or the like.
A pharmaceutical composition comprises a therapeutically-effective amount of one or more antibodies of the present disclosure and optionally a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers include, for example, water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Pharmaceutically acceptable carriers can further comprise minor amounts of auxiliary substances, such as wetting or emulsifying agents, preservatives, or buffers that enhance the shelf-life or effectiveness of the fusion protein. The compositions can be formulated to provide quick, sustained, or delayed release of the active ingredient(s) after administration. Suitable pharmaceutical compositions and processes for preparing them are known in the art. See, e.g., Remington, THE SCIENCE AND PRACTICE OF PHARMACY, A. Gennaro, et al., eds., 21st ed., Mack Publishing Co. (2005).
In certain embodiments, the pharmaceutical composition may be administered alone or in combination therapy, (i.e., simultaneously or sequentially) with an immuno-suppressive/immunomodulatory and/or anti-inflammatory agent. An exemplary type of agent is a cytotoxic T lymphocyte-associated protein 4 (CTLA4) mutant molecule. An exemplary CTLA4 mutant molecule is L104EA29Y-Ig (belatacept) which is a modified CTLA4-Ig. Different immune diseases can require use of specific auxiliary compounds useful for treating immune diseases, which can be determined on a patient-to-patient basis. For example, the pharmaceutical composition may be administered in combination with one or more suitable adjuvants, e.g., cytokines (IL-10 and IL-13, for example) or other immune stimulators, e.g., chemokines, tumor-associated antigens, and peptides. Suitable adjuvants are known in the art.
In certain embodiments, a method of treating an immune disease in a patient in need of such treatment may comprise administering to the patient a therapeutically effective amount of the antibody, or antigen binding portion thereof, as described herein. Further provided is a method of treating or preventing an autoimmune or inflammatory disease in a patient in need of such treatment may comprise administering to the patient a therapeutically effective amount of the antibody, or antigen binding portion thereof, as described herein. Also provided is the use of an antibody, or antigen binding portion thereof, of the disclosure, or a pharmaceutically acceptable salt thereof, for treating an immune disease in a patient in need of such treatment and/or for treating or preventing an autoimmune or inflammatory disease in a patient in need of such treatment, that may comprise administering to the patient a therapeutically effective amount of the antibody, or antigen binding portion thereof. Antagonizing CD40-mediated T cell activation could inhibit undesired T cell responses occurring during autoimmunity, transplant rejection, or allergic responses, for example. Inhibiting CD40-mediated T cell activation could moderate the progression and/or severity of these diseases.
In certain embodiments, the use of an antibody, or antigen binding portion thereof, of the disclosure, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treatment of an immune disease and/or for treating or preventing an autoimmune or inflammatory disease in a patient in a patient in need of such treatment, is also provided. The medicament can, for example, be administered in combination with an immunosuppressive/immunomodulatory and/or anti-inflammatory agent.
As used herein, a “patient” means an animal, e.g., mammal, including a human. For example, the patient may be diagnosed with an immune disease. “Treatment” or “treat” or “treating” refers to the process involving alleviating the progression or severity of a symptom, disorder, condition, or disease. An “immune disease” refers to any disease associated with the development of an immune reaction in an individual, including a cellular and/or a humoral immune reaction. Examples of immune diseases include, but are not limited to, inflammation, allergy, autoimmune disease, or graft-related disease. Thus, the patient may be diagnosed with an autoimmune disease or inflammatory disease. An “autoimmune disease” refers to any disease associated with the development of an autoimmune reaction in an individual, including a cellular and/or a humoral immune reaction. An example of an autoimmune disease is inflammatory bowel disease (IBD), including, but not limited to ulcerative colitis and Crohn's disease. Other autoimmune diseases include systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, diabetes, psoriasis, scleroderma, and atherosclerosis. Graft-related diseases include graft versus host disease (GVHD), acute transplantation rejection, and chronic transplantation rejection.
In certain embodiments, diseases that can be treated by administering the antibody of the disclosure may be selected from the group consisting of: Addison's disease, allergies, anaphylaxis, ankylosing spondylitis, asthma, atherosclerosis, atopic allergy, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, autoimmune parotitis, bronchial asthma, coronary heart disease, Crohn's disease, diabetes, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel disease, immune response to recombinant drug products (e.g., Factor VII in hemophiliacs), lupus nephritis, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathies, thyroiditis, transplant rejection, vasculitis, and ulcerative colitis.
Any suitable method or route can be used to administer the antibody, or antigen binding portion thereof, or the pharmaceutical composition. Routes of administration include, for example, intravenous, intraperitoneal, subcutaneous, or intramuscular administration. A therapeutically effective dose of administered antibody depends on numerous factors, including, for example, the type and severity of the disease being treated, the use of combination therapy, the route of administration of the antibody, or antigen binding portion thereof, or pharmaceutical composition, and the weight of the patient. A non-limiting range for a therapeutically effective amount of an antibody is 0.1-20 milligram/kilogram (mg/kg), and in an aspect, 1-10 mg/kg, relative to the body weight of the patient.
A kit useful for treating an immune disease in a human patient is provided. A kit useful for treating or preventing an autoimmune disease or inflammatory disease in a human patient is also provided. The kit can comprise (a) a dose of an antibody, or antigen binding portion thereof, of the present disclosure and (b) instructional material for using the antibody, or antigen binding portion thereof, in the method of treating an immune disease, or for using the antibody, or antigen binding portion thereof, in the method of treating or preventing an autoimmune or inflammatory disease, in a patient.
“Instructional material,” as that term is used herein, includes a publication, a recording, a diagram, or any other medium of expression, which can be used to communicate the usefulness of the composition and/or compound of the invention in a kit. The instructional material of the kit may, for example, be affixed to a container that contains the compound and/or composition of the invention or be shipped together with a container, which contains the compound and/or composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the recipient uses the instructional material and the compound cooperatively. Delivery of the instructional material may be, for example, by physical delivery of the publication or other medium of expression communicating the usefulness of the kit, or may alternatively be achieved by electronic transmission, for example by means of a computer, such as by electronic mail, or download from a website.
Embodiment 1: An isolated antibody, or antigen binding portion thereof, that specifically binds to human CD40, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein:
(i) said heavy chain variable region comprises an amino acid sequence selected from: HC2, HC3, HC4, HC5, HC6, HC7, HC8, HC9, HC16, HC10, HC15, HC11, HC12, and HC 14; and said light chain variable region comprises LC1 as shown in Table 3;
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
QA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITAD
STSTAY
STSTAY
(ii) said heavy chain variable region comprises an amino acid sequence selected from: HC1, HC2, HC3, HC4, HC5, HC6, HC7, HC8, HC9, HC16, HC10, HC15, HC11, HC12, and HC 14, and H13; and said light chain variable region comprises LC2 as shown in Table 4;
PGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSCASGYAFTSYWMHWVRQA
KPGSSVSVSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
QA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITAD
STSTAY
STSTAY
WMGQINPTTGRSQYN
KFKTRVTITADKSTSTAY
(iii) said heavy chain variable region comprises an amino acid sequence selected from: HC1, HC2, HC3, HC4, HC5, HC6, HC7, HC8, HC9, HC16, HC10, HC15, HC11, HC12, and HC 14, and H13; and said light chain variable region comprises LC3 as shown in Table 5;
LLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQP
PGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVSVSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
QA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITAD
STSTAY
STSTAY
WMGQINPTTGRSQYN
KFKTRVTITADKSTSTAY
(iv) said heavy chain variable region comprises an amino acid sequence selected from: HC1, HC2, HC3, HC4, HC5, HC6, HC7, HC8, HC9, HC16, HC10, HC15, HC11, HC12, and HC 14, and H13; and said light chain variable region comprises LC4 as shown in Table 6;
LLIYSASY
YTGVPS
FSGSGSGTDFTLTISSLQP
PGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSV
VSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
QA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITAD
STSTAY
STSTAY
WMGQINPTTGRSQYN
KFKTRVTITADKSTSTAY
(v) said heavy chain variable region comprises an amino acid sequence selected from: HC1, HC2, HC3, HC4, HC5, HC6, HC7, HC8, HC9, HC16, HC10, HC15, HC11, HC12, and HC 14, and H13; and said light chain variable region comprises LC5 as shown in Table 7;
FSGSGSGTDFTLTISSLQP
PGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSV
VSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
QA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITAD
STSTAY
STSTAY
WMGQINPTTGRSQYN
KFKTRVTITADKSTSTAY
or
(vi) said heavy chain variable region comprises an amino acid sequence selected from: HC1, HC2, HC3, HC4, HC5, HC6, HC7, HC8, HC9, HC16, HC10, HC15, HC11, HC12, and HC 14, and H13; and said light chain variable region comprises LC6 as shown in Table 8;
PGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSVKVSCKASGYAFTSYWMHWVRQA
PGSSVKVSC
ASGYAFTSYWMHWVRQA
KPGSSV
VSC
ASGYAFTSYWMHWVRQA
ASGYAFTSYWMHWVRQA
QA
FKT
VTITADKSTSTAY
FKT
VTITADKSTSTAY
FKTRVTITADKSTSTAY
VTITADKSTSTAY
VTITADKSTSTAY
SQYNEKFKTRVTITADKSTSTAY
SQYNEKFKTRVTITAD
STSTAY
STSTAY
WMGQINPTTGRSQYN
KFKTRVTITADKSTSTAY
Embodiment 2. An isolated antibody, or antigen binding portion thereof, that specifically binds to human CD40, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein:
(i) said heavy chain variable region comprises HC1
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCQQ
HYSTPWTFGGGTKVEIK; SEQ ID NO. 41);
(ii) said heavy chain variable region comprises HC1
YSTPWTFGGGTKVEIK; SEQ ID NO. 42);
(iii) said heavy chain variable region comprises HC15
VTITADKSTSTAYMELSSLRSEDTA
YSTPWTFGGGTKVEIK; SEQ ID NO. 42);
(iv) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEWM
(v) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEW
LL
TFGGGTKVEIK: SEQ ID NO. 42);
or
(vi) said heavy chain variable region comprises HC5
PGSSVKVSC
ASGYAFTSYWMHWVRQAPGQGLE
LL
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTP
WTFGGGTKVEIK; SEQ ID NO. 41).
Embodiment 3. The isolated antibody, or antigen binding portion thereof, of embodiment 2, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein:
(i) said heavy chain variable region comprises HC1
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
QTYICNVNHKPSNTKVDKRV; SEQ ID NO. 47);
LL
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCQQHYST
PWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR
EAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK
VYACEVTHQGLSSPVTKSFNRGEC; SEQ ID NO. 20);
(ii) said heavy chain variable region comprises HC1
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
QTYICNVNHKPSNTKVDKRV; SEQ ID NO. 47);
LLI
QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
VTHQGLSSYNTKSFNRGEC; SEQ ID NO. 19);
(iii) said heavy chain variable region comprises HC15
VTITADKSTSTAYMELSSLRSEDTAVYYC
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
TQTYICNVNHKPSNTKVDKRV; SEQ ID NO. 86);
L
WTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA
KVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
CEVTHQGLSSYNTKSFNRGEC; SEQ ID NO. 19);
(iv) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEW
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
TQTYICNVNHKPSNTKVDKRV; SEQ ID NO. 49);
QWKVDNALQSGNSQESVTEQDSKDSTYSLSSYETLSKADYEKHKVYACE
VTHQGLSSPVTKSFNRGEC; SEQ ID NO. 17);
(v) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEW
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG
TQTYICNVNHKPSNTKVDKRV; SEQ ID NO. 49);
L
WTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA
KVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA
CEVTHQGLSSYNTKSFNRGEC; SEQ ID NO. 19);
or
(vi) said heavy chain variable region comprises HC5
PGSSVKVSC
ASGYAFTSYWMHWVRQAPGQGLE
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL
GTQTYICNVNHKPSNTKVDKRV; SEQ ID NO. 50);
LL
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCQQHYST
PWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPRE
AKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY
ACEVTHQGLSSPVTKSFNRGEC; SEQ ID NO. 20).
Embodiment 4. The isolated antibody, or antigen binding portion thereof, of embodiment 2, wherein said first polypeptide portion comprises or consists of an amino acid sequence selected from the group consisting of:
(i)
VTITADKSTSTAYMELSSLRSEDTA
AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV
TVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPE
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLE
ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT
VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEL
(iii)
PGSSVKVSC
ASGYAFTSYWMHWVRQAPGQG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAP
Embodiment 5. The isolated antibody, or antigen binding portion thereof, of embodiment 2, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein:
(i) said heavy chain variable region comprises HC1
ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT
VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEL
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCQQ
HYSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS
KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC; SEQ ID NO.
(ii) said heavy chain variable region comprises HC1
ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT
VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEL
YSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLN
NFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK
ADYEKHKVYACEVTHQGLSSYNTKSFNRGEC; SEQ ID NO.
(iii) said heavy chain variable region comprises HC15
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAP
TPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY
PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE
KHKVYACEVTHQGLSSYNTKSFNRGEC; SEQ ID NO. 19);
(iv) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGL
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKYHACPPCP
YSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVNCLLN
NFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSYETLSK
ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC; SEQ ID NO. 17);
(v) said heavy chain variable region comprises HC4
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGL
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKYHACPPCP
YSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASWCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA
DYEKHKVYACEVTHQGLSSYNTKSFNRGEC; SEQ ID NO. 19);
or
(vi) said heavy chain variable region comprises HC5
PGSSVKVSC
ASGYAFTSYWMHWVRQAPGQGL
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS
SWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKYHACPPCP
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCQQH
YSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASWCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA
DYEKHKVYACEVTHQGLSSPVTKSFNRGEC; SEQ ID NO. 20).
Embodiment 6. The isolated antibody, or antigen binding portion thereof, of embodiment 2, wherein said heavy chain variable region comprises HC1 (QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEWMGQINPT TGRSQYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCARWGLQPFAYWGQG TLVTVSS; SEQ ID NO. 40); and said light chain variable region comprises LC4 (DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPQLLIYSASYQYT GVPSQFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK; SEQ ID NO. 41).
Embodiment 7. The isolated antibody, or antigen binding portion thereof, of embodiment 2, wherein said heavy chain variable region comprises HC1 (QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEWMGQINPT TGRSQYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCARWGLQPFAYWGQG TLVTVSS; SEQ ID NO. 40); and said light chain variable region comprises LC3 (DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPELLIYSASYRYTG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK; SEQ ID NO. 42).
Embodiment 8. The isolated antibody, or antigen binding portion thereof, of embodiment 2, wherein said heavy chain variable region comprises HC15 (QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEWMGQINPT TGRSQYNEKFKTQVTITADKSTSTAYMELSSLRSEDTAVYYCARWGLQPFAYWGQG TLVTVSS; SEQ ID NO. 43); and said light chain variable region comprises LC3 (DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPELLIYSASYRYTG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK; SEQ ID NO. 42).
Embodiment 9. The isolated antibody, or antigen binding portion thereof, of embodiment 2, wherein said heavy chain variable region comprises HC4 (QVQLVQSGAEVEKPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEWMGQINPT TGRSQYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCARWGLQPFAYWGQG TLVTVSS; SEQ ID NO. 44); and said light chain variable region comprises LC1 (DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYT GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK; SEQ ID NO. 45).
Embodiment 10. The isolated antibody, or antigen binding portion thereof, of embodiment 2, wherein said heavy chain variable region comprises HC4 (QVQLVQSGAEVEKPGSSVKVSCKASGYAFTSYWMHWVRQAPGQGLEWMGQINPT TGRSQYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCARWGLQPFAYWGQG TLVTVSS; SEQ ID NO. 44); and said light chain variable region comprises LC3 (DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPELLIYSASYRYTG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK; SEQ ID NO. 42).
Embodiment 11. The isolated antibody, or antigen binding portion thereof, of embodiment 2, wherein said heavy chain variable region comprises HC5 (QVQLVQSGAEVEQPGSSVKVSCEASGYAFTSYWMHWVRQAPGQGLEWMGQINPT TGRSQYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCARWGLQPFAYWGQG TLVTVSS; SEQ ID NO. 46); and said light chain variable region comprises LC4 (DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPQLLIYSASYQYT GVPSQFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK; SEQ ID NO. 41).
Embodiment 12. The antibody or antigen binding portion thereof of any of embodiments 2-11, wherein the antigen binding portion is an scFv-Fc.
Embodiment 13. The antibody or antigen binding portion thereof of any one of embodiments 2-12, wherein the antibody or antigen-binding portion thereof is linked to a therapeutic agent.
Embodiment 14. The antibody or antigen binding portion thereof of any one of embodiments 2-13, wherein the antibody or antigen-binding portion thereof is linked to a second functional moiety having a different binding specificity than said antibody or antigen binding portion thereof.
Embodiment 15. The antibody or antigen binding portion thereof of any one of embodiments 2-14, further comprising an additional moiety.
Embodiment 16. A method of treating or preventing an immune response in a subject comprising administering to the subject the antibody, or the antigen binding portion thereof, of any one of embodiments 2-15.
Embodiment 17. A method of treating or preventing an autoimmune or inflammatory disease in a subject, comprising administering to the subject the antibody, or the antigen binding portion thereof, of any one of embodiments 2-15.
Embodiment 18. The method of embodiment 16 or 17, wherein the antibody, or the antigen binding portion thereof is administered with an immunosuppressive/immunomodulatory and/or anti-inflammatory agent.
Embodiment 19. The method of embodiment 18, wherein said immunosuppressive/immunomodulatory and/or anti-inflammatory agent is a CTLA4 mutant molecule.
Embodiment 20. The method of embodiment 19, wherein said a CTLA4 mutant molecule L104EA29Y-Ig (belatacept).
Embodiment 21. The method of embodiment 16 or 17, wherein the subject has a disease selected from the group consisting of: Addison's disease, allergies, anaphylaxis, ankylosing spondylitis, asthma, atherosclerosis, atopic allergy, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, autoimmune parotitis, bronchial asthma, coronary heart disease, Crohn's disease, diabetes, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel disease, an immune response to recombinant drug products (e.g., Factor VII in hemophiliacs), lupus nephritis, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathies, thyroiditis, transplant rejection, vasculitis, and ulcerative colitis.
Embodiment 22. An isolated antibody, or antigen binding portion thereof, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein
(i) said heavy chain variable region comprises the HC1 framework
XXXXXXFGGGTKVEIK; SEQ ID NO. 74)
and
Embodiment 23. The isolated antibody or antigen binding portion thereof of embodiment 22, wherein the neutral amino acid is selected from glutamine, asparagine, valine, serine, alanine, and threonine.
Embodiment 24. The isolated antibody or antigen binding portion thereof of embodiment 22, wherein the acidic amino acid is selected from glutamate or aspartate.
Embodiment 25. The isolated antibody or antigen binding portion thereof of embodiment 22, wherein at least two mutations are present in the light chain variable region at basic residues selected from the group consisting of 45, 54, 61, and 107, and combinations thereof, of SEQ ID NO: 74.
Embodiment 26. The isolated antibody or antigen binding portion thereof of embodiment 22, wherein at least two mutations are present in the heavy chain variable region at basic residues selected from the group consisting of 12, 13, 19, 23, 38, 57, 63, 67, and 74 of SEQ ID NO: 73.
Embodiment 27. The isolated antibody or antigen binding portion thereof of embodiment 22, wherein said light chain variable region comprises the LC1 framework
or mutation thereof and wherein positions of 45, 54, 61, 107, and 108, and combinations thereof, can be mutated.
Embodiment 28. The isolated antibody or antigen binding portion thereof of embodiment 22, for specifically binding to human CD40.
Embodiment 29. A method for improving at least one pharmacokinetic property of a first antibody, the method comprising mutating a residue at at least one position selected from 12, 13, 19, 23, 38, 57, 63, 67, and 74, or combinations thereof, of SEQ ID NO: 73 and/or at at least one position selected from 45, 54, 61, and 107, or combinations thereof, of SEQ ID NO: 74 to produce a variant of the first antibody having at least one mutated residue and at least one improved pharmacokinetic property, relative to the non-modified first antibody.
Embodiment 30. The method of embodiment 29, wherein the first antibody specifically binds to human CD40.
Embodiment 31. An isolated antibody, or antigen binding portion thereof, wherein said antibody comprises a first polypeptide portion comprising a heavy chain variable region, and a second polypeptide portion comprising a light chain variable region, wherein:
(i) said heavy chain variable region comprises the HC1 framework
XXGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCXXX
XXXXXXFGGGTKVEIK; SEQ ID NO. 80);
(ii) said heavy chain variable region comprises the HC1 framework
XXXXXXFGGGTKVEIK; SEQ ID NO. 81);
(iii) said heavy chain variable region comprises the HC15 framework
VTITADKSTSTAYMELSSLRSEDT
XXXXXXFGGGTKVEIK; SEQ ID NO. 81);
(iv) said heavy chain variable region comprises the HC4 framework
KPGSSVKVSCKASGYAFTXXXXXWVRQAPGQGL
XXXXXXFGGGTKVEIK; SEQ ID NO. 74);
(v) said heavy chain variable region comprises the HC4 framework
KPGSSVKVSCKASGYAFTXXXXXWVRQAPGQGL
XXXXXXFGGGTKVEIK; SEQ ID NO. 81);
or
(vi) said heavy chain variable region comprises the HC5 framework
PGSSVKVSC
ASGYAFTXXXXXWVRQAPGQGLEW
LL
XXGVPS
FSGSGSGTDFTLTISSLQPEDFATYYCXXXXXXX
XXFGGGTKVEIK; SEQ ID NO. 80).
Embodiment 32. The isolated antibody or antigen binding portion thereof of embodiment 31, wherein said first polypeptide portion comprises a human heavy chain constant region; and said second polypeptide portion comprises a human light chain constant region.
Embodiment 33. A nucleic acid molecule encoding an isolated antibody or antigen binding portion thereof of any one of embodiments 1 to 15, 22 to 28, 31, and 32.
Embodiment 34. An expression vector comprising the nucleic acid molecule of embodiment 33.
Embodiment 35. A cell transformed with the expression vector of embodiment 34 or the nucleic acid of embodiment 33.
Embodiment 36. A method of preparing an anti-human CD40 antibody, or antigen binding portion thereof, comprising:
a) expressing the antibody, or antigen binding portion thereof, in the cell of embodiment 35; and
b) isolating the antibody, or antigen binding portion thereof, from the cell.
Embodiment 37. A pharmaceutical composition comprising: a) the antibody, or antigen binding portion thereof, of any one of embodiments 1 to 15, 22 to 28, 31, and 32; and b) a pharmaceutically acceptable carrier.
Embodiment 38. An antibody, or antigen binding portion thereof, of any one of embodiments 1 to 15, 22 to 28, 31, and 32 for use as a medicament.
Embodiment 39. An antibody, or antigen binding portion thereof, of any one of embodiments 1 to 15, 22 to 28, 31, and 32 for use in the treatment of a subject in need thereof.
Anti-CD40 monoclonal antibody BMS-986325 (PCT/US19/62011) was chosen for developing a protein engineering strategy to optimize pharmacokinetic (PK) properties. The amino acid sequence of the heavy chain variable region and the light chain variable region of BMS-986325 are shown in Table 15. The CDRs for each variable region are underlined and in bold font.
The protein engineering strategy was to disrupt positively charged (basic) patches on the antibody surface that might be involved in undesirable binding to negatively charged (acidic) intracellular surfaces, such as cell membranes or extracellular matrix (ECM). As part of this strategy, it was also critical to maintain the high affinity interactions with CD40 and functional potency, as well as the favorable biophysical properties of the antibody.
To limit potential immunogenicity risk, the initial optimization focused on the variable region of the heavy and light chains, which are naturally more prone to sequence variability. These variable heavy (Vh) and variable light (Vl) chain regions were analyzed at both the primary amino acid sequence level, as well as by generating a structural model of the BMS-986325 Fab domains. The homology model was created based on the available X-ray structures using the Antibody Modeler in Molecular Operating Environment (MOE) (Chemical Computing Group). The amino acid sequence was loaded into the modeling GUI. The tool then searches for framework and CDR loop templates. The antibody backbone is built from the most similar framework templates followed by CDR loop generation. The final step of model building is refinement performed by all atom minimization with Amber10EHT force field in MOE.
Sequence analysis first involved identifying all the lysine (Lys) and arginine (Arg) residues in the heavy chain variable region (Vh) and light chain variable region (Vl), which would be the primary source of positive charge at physiological pH and temperature. The location of these amino acid residues in BMS-986325 were evaluated with respect to the native human germline repertoire to identify residues that might have undergone mutation to improve CD40 binding, as well as evaluated with respect to a set of antibodies from the same sequence family that were identified from the same CD40 immunization that identified BMS-986325. See Table 16. (The light chain variable region for BMS-986325 is a kappa light chain “Vk”).
The sequence analysis was used to help bias the protein engineering efforts away from residues that could potentially be involved in CD40 binding. Analysis of the structural model included: (1) evaluating the location of each of the Lys and Arg residues with respect to charged and hydrophobic patches on the antibody surface, and (2) evaluating the impact that mutation to non-basic residues would likely have on these surface properties. A charged patch refers to more than 1 charged residue in spatial proximity to each other on the surface of the folder protein structure. A hydrophobic patch refers to more than 1 non-charged residue in spatial proximity to each other on the surface of the folder protein structure
In total, 7 Lys and 5 Arg residues were identified in the Vh sequence, and 6 Lys and 3 Arg in the Vl sequence of BMS-986325. In addition, since the last residue of the Vl (K107) and the first residue of the light chain constant region (R108) are basic residues, the R108 residue was considered as part of the substrate for mutation. Based on the above sequence and structural model analysis, each of the Lys and Arg residues were annotated with respect to: (1) their clustering into charge patches, (2) likelihood that mutation would impact binding based on (i) CDR proximity and (ii) binding data for sequence family variants, (3) germline analysis, and (4) other predicted properties based on structural modelling. See Table 17.
The basic residues were mutated to either: (1) an uncharged amino acid or (2) an acidic residue. To select the amino acid residues to mutate the basic residues to, Gln was prioritized as an amino acid that would replace the basic side chain of Lys or Arg with an uncharged side chain of similar length. Glu was prioritized as an acidic residue that would result in a more dramatic disruption of a positively charged patch by reversing the positive charge of Lys or Arg with a negatively charged side chain of similar length. Gln and Glu were also prioritized over Asn and Asp residues respectively to avoid potential deamidation (Asn) or isomerization (Asp) issues that are common for the shorter Asn and Asp side chains. Glu and Gln were also prioritized since they have relatively low immunogenic potential. In addition, the Lys and Arg positions were compared across the human germline repertoire to identify alternative native germline residues that could replace the basic Lys or Arg side chain with neutral or acidic residues that are known to be structurally tolerated in other human IgG, and also likely to carry low immunogenicity risk.
Based on the above analysis each of Lys and Arg residues in the Vh and Vl regions were assigned a relative priority for mutagenesis, and then further consolidated into a short list of 14 mutant HC and 5 mutant LC consisting of single mutations or combinations of mutations that could represent a subset of the highest priority mutations. See Table 18 and Table 19.
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
PGSSVKVSCKASGYAFTSYWMHWVRQAPGQG
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
PGSSVKVSC
ASGYAFTSYWMHWVRQAPGQG
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
KPGSSVKVSCKASGYAFTSYWMHWVRQAPGQG
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
PGSSVKVSC
ASGYAFTSYWMHWVRQAPGQG
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
KPGSSVSVSC
ASGYAFTSYWMHWVRQAPGQG
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
ASGYAFTSYWMHWVRQAPGQG
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
QAPGQG
FKT
VTITADKSTSTAYMELSSLRS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
FKT
VTITADKSTSTAYMELSSLRS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
VTITADKSTSTAYMELSSLRS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
SQYNEKFKTRVTITADKSTSTAYMELSSLRS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
SQYNEKFKTRVTITAD
STSTAYMELSSLRS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
WMGQINPTTGRSQYN
KFKTRVTITADKSTSTAYMELSSLRS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
STSTAYMELSSLRS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
VTITADKSTSTAYMELSSLRS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
FKTRVTITADKSTSTAYMELSSLRS
KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
QQHYSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV
FCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
LLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
QQHYSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV
VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
LLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
QQHYSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV
VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
LLIYSASY
YTGVPS
FSGSGSGTDFTLTISSLQPEDFATYYC
QQHYSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV
VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
FSGSGSGTDFTLTISSLQPEDFATYYC
QQHYSTPWTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV
VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
QQHYSTPWTFGGGTKVETTVAAPSVFIFPPSDEQLKSGTASV
VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Moreover, one additional mutant HC (HC13) was designed as a proof of concept control, to replace two acidic residues with two basic residues (E46K, E62K) and introduce a more positively charged surface patch that would be predicted to potentially demonstrate increased off-target binding and reduced PK, i.e., the opposite properties to the other engineered variants.
Collectively these 15 mutant HC and 5 mutant LC together with the wild type HC and wild type LC resulted in a total of 16 HC and 6 LC constructs (TABLE 18) that could be combined in all possible HC×LC combinations to yield 96 unique antibodies. The overall change in net charge for these different combinations of HC and LC range from minus 8 (−8) for the combination of HC5 (HC-K12E, K13Q, K23E) with LC4 (LC-K45Q, R54Q, R61Q), to plus 4 (+4) for the proof of concept antibody combination of HC13 (HC-E46K, E62K) with the wild type LC1 (LC-wt). See Table 19.
The 96 antibodies of the 16 HC×6 LC combinations were assigned antibody mutant identification numbers (M #) from M1-M96 (Table 20).
The 96 antibodies generated from the 16 HC×6 LC combinations were produced by transient transfection and 3 mL scale, and analyzed for titer using ForteBio Octet RED96 instrument.
Antibody expression (titer) was detected for each HC×LC combination. The titer varied across a broad range from as low as 5 μg/ml (M56) to as high as 322 μg/ml (M80), with the wild type antibody (M1/wt) having a titer of 134 μg/ml. See Table 21.
Several trends were observed in the titer data associated with specific HC or LC mutations. For example, the double or triple mutations to HC patch #2 (HC8=HC-R38Q, K63Q, R67Q, and HC9=HC-K63Q, R67E) significantly reduced the antibody titer in combination with any of the six LCs, with the triple mutant (HC8) demonstrating especially low titer (5-7 μg/ml) when paired with any of the six different LCs. Interestingly, the LC mutations generally improved the antibody titer, with 73/80 (91%) of antibodies that contained a mutated LC having higher titer than the respective HC paired with wild type LC. See Table 21.
The 96 mutant BMS-986325 antibodies were tested for CD40 binding by surface plasmon resonance (SPR). The titer data (Table 21) were used to normalize the antibody concentration in each supernatant to 3 μg/ml, and these antibodies were captured out of the supernatants on a protein A CMS Series S sensor chip (GE Healthcare), and tested for binding to two concentrations (5 nM and 50 nM) of soluble hCD40 extracellular domain. The purified wild-type BMS-986325 was included as a control at the beginning, middle and end of the experiment for a total of n=3 on each of three flow cells, and showed excellent reproducibility over the course of the experiment on each flow cell (Table 22).
The KD values for CD40 binding to the 96 supernatant samples are summarized in Table 23, and a plot of the kinetic on-rate (ka) and off-rate (kd) values (iso affinity plot) is provided in
The titer data, hCD40 binding SPR data, and in silico analysis of the antibody sequences and structural models were collectively considered to identify a subset of antibodies to express at larger scale and purify for additional characterization. For this analysis, properties such as low titer or reduced affinity compared to the wild type antibody were considered undesirable and more likely to be deprioritized. However, rather than bias toward production of only those specific HC×LC combinants with the highest affinity and titer, the aim was to have the purified set of antibodies represent a diverse range of different properties, including at least one mutation to each of the 5 basic patches. For example, all patch 3 mutants were well tolerated with favorable titer and CD40 binding properties, and appeared to be favorably combined with any of the patch 4 or patch 5 LC mutants, but antibodies containing HC4, HC5, and HC6 were prioritized over those with HC2 or HC3 because HC4, HC5 and HC6 variants had larger changes in net charge without any undesirable reduction in titer or loss of binding. Both M13 and M53 were included to ensure that the purified set represented the full range of change in net charge from M13 (+4) to M53 (−8). For further diversity in the purified set, the set included not only variants with Lys and Arg mutated to Glu or Gln, but also variants where Lys or Arg were mutated to human germline residues, including M62 containing HC14 (HC-K74T) and M38 and M54 which contain HC6 (HC-K12V, K19S, K23A). Moreover, several variants with only a single mutation to HC or LC were included to keep the total mutation burden low and reduce the risk of instability or immunogenicity. When all these factors were considered a final set of wild type and 15 mutant antibodies were identified for larger scale expression, purification and characterization. The final set are shown in TABLE 24.
The 16 antibodies from Table 24 were expressed in transient Expi293 cells (purchased from ThermoFisher Scientific) under conditions indicated for these cells. The antibodies were purified for additional analytical and biophysical characterization. The additional characterization included production of two batches of M4, identified as M4 and M4-b, to compare material generated from two separate production runs; the two separate production runs were found to have similar analytical and biophysical properties.
The purity and oligomeric state of BMS-986325 and the 15 variants were characterized by analytical size exclusion chromatography (aSEC). The data are show in Table 25.
All samples were found to be of suitable quality for additional studies, with a percent monomer of greater than 93%, and less than 7% high molecular weight (HMW) species and no detectable low molecular weight (LMW) species.
The impact of the various mutations on the charge properties of BMS-986325 were evaluated using imaged capillary isoelectric focusing (icIEF). These data are shown in Table 26.
Wild-type BMS-986325 had a main peak isoelectric point (pI) of 9.21, with 76.1% main peak, 22.2% acidic variants and 1.7% basic variants. See M1 in Table 26. The icIEF profiles for all the other antibodies also consistent of predominantly main peak (71.7-94.2%) with some acidic variants (5.8-26.1%) and either a small amount or no basic variants (0-2.4%).
As anticipated, M13, the only mutant designed to increase positive charge, was found to have a higher main peak pI (9.42) than wild type BMS-986325, whereas all of the other mutants which were designed to replace positively charged residues with neutral or acidic residues were found to have lower pI than wild type BMS-986325.
The hydrophobicity of wild type and mutant BMS-986325 molecules were evaluated by analytical hydrophobic interaction chromatography (aHIC). The data are provided in Table 27.
In this analysis, wild type BMS-986325 eluted as a single symmetrical peak with main peak retention time (RT) of 10.1 min See M1 in Table 27. Several of the mutations, which were designed to disrupt positively charged patches, did so while maintaining low hydrophobicity (RT=10.1-10.3 min), including M4, M10, M13, M33, M36, M47, M80, M81. This subset of antibodies includes variants having one or two charged residues mutated to uncharged residues, such as M47, M80, and M81. In contrast, all variants utilizing LC4 (LC-K45Q, R54Q, R61Q) which was the most highly mutated light chain tested and replaced three charged residues with three uncharged residues, had increased hydrophobicity compared to wild type (RT=10.5-10.8 min).
The heterogeneity of the BMS-986325 variants also generally increased with more mutation. For example, all antibodies utilizing a HC or a LC containing three mutations (HC5, HC6, LC4) eluted as <80% main peak with a corresponding increased levels of post-peak (later eluting) more hydrophobic species. The two variants which had three mutations to each of the HC and LC for a total of six mutations (M53 and M54) had particularly high heterogeneity, with main peak of 53.4-55.2% and post peak of 46.6-44.8%.
The structural and colloidal stability of the BMS-986325 variants were investigated by fluorescence spectroscopy and static light scattering (SLS) respectively, using an UNcle instrument (Unchained Labs, Pleasanton, Calif.). The thermal denaturation of each antibody was accompanied by a distinct change in fluorescence, which could be monitored using the barycentric mean (BCM) method and fit to determine a melting temperature 1 (Tmi) value. This was followed at higher temperatures by a large increase in SLS that is indicative of aggregation of the denatured protein molecules, from which the aggregation onset temperature (Tagg) can be determined by monitoring at either 266 nm (Tagg266) or 473 nm (Tagg473).
The data are shown in Table 28.
The Tm and Tagg values (average±standard deviation for triplicate measurement) for wild type BMS-986325 were Tm1=65.8±0.3° C., Tagg266=79.7±0.1° C., and Tagg473=79.8±0.4° C. Tm1 values for all of the antibody variants were between 65.1 and 67.6° C., with all variants except for M37 having comparable (within standard deviation) or slightly higher Tm1 compared to wild type BMS-986325. In contrast, the Tagg varied over a larger range for both Tagg266 (70.6-79.9° C.) and Tagg473 (70.6-80.3° C.), with all variants except M33 having lower Tagg values than wild type.
A direct correlation between the number of mutations and the Tagg values for this set of antibodies was not observed, suggesting that the location of the mutation and identity of the amino acid change are scientifically important for maintaining the thermal stability of the antibody. For example, the Tagg for M62 (4 total mutations) was higher than that for several mutants that had only 1, 2 or 3 mutations (M4, M10, M13, M36, M47, M49, M80, M81), whereas a single mutation in M10 resulted in a significant destabilization, with Tagg266=72.6° C. and Tagg473=72.2° C.
To evaluate the potential for nonspecific binding of the positively charged BMS-986325 surface patches to acidic surfaces, and the impact of mutation on those interactions, an extracellular matrix (ECM) binding ELISA assay was utilized. The data are shown in Table 29.
Wild type BMS-986325 (M1) generated a strong ECM binding response with ECM score of 23.5 at the 1 μM concentration. As would be predicted, the proof of concept control molecule, M13 into which an additional positively charge patch was introduced by the E46K-E62K double mutation, was found to demonstrate a much stronger ECM binding response than wild type BMS-986325 with ECM score of 72.0 at the 1 μM concentration. The single HC-R67E mutation (M10) had the smallest impact on ECM score compared to wild type antibody, with ECM score of 21.7 at 1 μM concentration. M4, M80 and M81 demonstrated some reduction in ECM binding but maintained measureable ECM binding (ECM score=8.1.-14.0 at 1 μM). All of the other variants (M33, M36, M37, M38, M47, M49, M53, M54, M62, M63) demonstrated significantly reduced ECM binding responses with ECM scores of 1.4-3.1 at 1 μM.
The CD40 target binding kinetics and affinity of BMS-986325 and the 15 purified variants were evaluated using a SPR method similar to SPR method previously used to screen the 96 small scale expression supernatants, except that rather than just two analyte concentrations in the supernatant screening experiment, a full set of 6 CD40 analyte concentrations were tested for the purified antibodies. Additionally, to more accurately define the dissociation rate (kd), a longer dissociation time of 360 seconds (s) was used as opposed to the shorter 180 s dissociation that had been used in the supernatant screening experiment.
The data are shown in Table 30.
The observed impact of the mutations on CD40 binding to the purified antibodies was similar to that observed with the supernatants, with M13 having significantly lower affinity than wild type BMS-986325, and the other variants have similar or modestly higher affinity.
The impact of the mutations on the functional potency of BMS-986325 to inhibit CD40L stimulated activity on primary human tonsillar B cells was tested. The data are provided in Table 31.
All mutants exhibited potent inhibition of soluble CD40L trimer (IZ-hCD40L) stimulated B cell proliferation, with most mutants exhibiting similar potency to BMS-986325, with IC50 values within 2-3 fold (typically the range of donor variability in these assays as illustrated by the two lots of mutant M4). Exceptions include several mutant, M62, M809, M10, and M38, which showed modestly lower potency.
Similarly, all mutants inhibited the B cell proliferation stimulated by cell surface CD40L (CHO-CD40L), which is typically more difficult to inhibit. In these experiments, several mutants were modestly less potent but with high variability between the two donors tested (M62, M80, M10, M63, M37, M38, M54); the remaining mutants exhibited potencies within 3 fold that observed for BMS-986325. Collectively this data suggests that most mutations had minimal impact on CD40 potency with a select number of mutations exhibiting only a modest a shift in potency.
There are prior art CD40 antibodies described as having the potential to have agonist activity. In contrast, BMS-986325 is a pure antagonist showing no agonism on B cells either alone or in combination with IL-4, which sensitizes B cells to proliferation and activation signals. The potential of the mutations to influence potential agonism was also tested by monitoring for B cell stimulation by assaying proliferation and cytokine production.
The “intrinsic” PK of BMS-986325 and its variants is presented in
After intravenous (IV) administration of BMS-986325 (single 1—mg/kg doses) to mice, BMS-986325 exhibited a mean low total serum clearance “CL” of 0.56 mL/h/kg, limited volume of distribution at steady state “Vss” of 0.14 L/kg, and an apparent elimination half-life “T-Half” of 168 hours (— 7 days). Within variability, all variants (M39, M33, M47, M4, M36 and M53) except M13, have comparable or better PK than WT (area under the concentration-time curve “AUC” and CL within 2 fold). In contrast, at this dose, and within variability, the PK of M13 variant is worse than that of WT (lower AUC by 3.2 fold and higher CL by 5.3 fold). Each of M39, M33, M47, M4, M36 and M53 had improved values for at least one of these PK parameters, and for most of variants, had improved values for at least two of these PK parameters.
Thus, at this dose, within variability, the overall PK of all variants except for M13 is similar or slightly better than that of wild type BMS-986325. That is, at this dose, within variability, M13 has worse PK (lower AUC and higher clearance) than wild type BMS-986325, whereas the PK of all other variants are similar or improved with respect to wild type BMS-986325.
Cloning of BMS-986325 variants: The coding sequences for CD40 mAb heavy chains BMS-986325-IgG1a-P238K-K12Q-K13Q and BMS-986325-IgGla-P238K-R63Q were codon optimized for Chinese hamster ovary cell (CHO) expression and the synthetic DNA fragments were cloned into a modified pTT5 mammalian expression vector. The rest of the CD40 mAb heavy chains were generated by mutagenesis using one of the above two constructs as template.
The coding sequence for CD40 mAb light chain BMS-986325-Vk-K45Q-hLC was also codon optimized for CHO expression, and the synthetic DNA fragment was cloned into the same pTT5 vector. The rest of the CD40 mAb light chains were generated by mutagenesis using the above light chain construct as template.
Expression of BMS-986325 and BMS-986325 variants: For initial screening experiments, antibodies were expressed at 3 ml scale using Thermo Fisher Scientific Expi293™ expression system (ThermoFisher Scientific, Waltham, Mass.). The DNA/Expifectamine™ ratio was 1:2.7; DNA amount was 0.5 mg/L. Cell seeding density was 2.7×106 (after transfection the cell density was 2.5×106). Cells were fed 24 hours post-transfection with 0.5M valproic acid to final 2 mM concentration and CHO CD EfficientFeed™ B to final volume at 5% from Gibco® (ThermoFisher Scientific, Waltham, Mass.; cat #A10240-02). Culture growth condition was 37° C., 8% CO2 with humidity. Supernatants were harvested on day 5 by centrifugation. Larger scale expression was done at 0.5 L scale.
Purification of BMS-986325 and BMS-986325 variants: Clarified antibody-rich supernatants were bound to a 5 mL MabSelect SuRe™ (Cytiva, Marlborough, Mass.) column, washed with five column volumes of 1× phosphate-buffered saline (PBS) pH 7.2 until baseline was reached. Antibody was eluted with 50 mM acetic acid pH 3.0 and run over a Superdex 26/10 desalting column to exchange the buffer to PBS pH7.2. All samples had greater than 5% impurities and were run over a Superdex® 200 26/600 prep grade (pg) preparative SEC (pSEC) column (GE Healthcare, Chicago, Ill.) to remove these impurities. Samples were then concentrated to at least 1 mg/mL, and filtered through a 0.2 μm filter prior to freezing.
Octet BLI Titer analysis: Antibody titer was determined using Octet RED384 and Protein A sensor tips by ForteBio. An 8-point standard curve was made using a human IgG1f isotype standard antibody in PBS-T buffer, with a concentration range of 150-1.17 μg/mL. The standard curve was done in triplicate. Sample supernatants were diluted 1:2 in PBS-T buffer (10 mM NaPO4, 130 mM NaCl, 0.05% tween 30 (PBS-T) pH 7.2). Standard curve and samples were placed in a black flat bottom 96-well plate (Corning), final volume in wells was 100 μL. Protein A sensor tips were hydrated in PBS-T buffer for −10 mins before run began. Association was 180 s at 30 μL/min and Protein A sensor tips were regenerated using 10 mM glycine pH 1.5. Data was obtained using the Octet Software Data Acquisition and Data Analysis.
CD40 binding SPR of antibody supernatants: Surface plasmon resonance (SPR) studies were conducted on a BIAcore™ T200 instrument (GE Healthcare, Chicago Ill.). A Series S Protein A sensor chip (GE Healthcare, Chicago Ill.) was equilibrated with SPR running buffer of 10 mM NaPO4, 130 mM NaCl, 0.05% tween 20, (PBS-T) pH 7.2 at 25° C. The 96 antibody supernatants were normalized to a concentration of 3 μg/ml by diluting with PBS-T using a PerkinElmer JANUS® G3 system (PerkinElmer, Akron, Ohio). After priming the system, the 3 μg/ml antibody samples were captured on the protein A surface for 30 s at 10 μl/min Binding of 50 nM and 500 nM human CD40 extracellular domain (produced in house) was evaluated using association time of 180 s at 30 μl/min, followed by a dissociation time of 180 s at 30 μl/min Regeneration between cycles was accomplished using two 15 s injections of 10 mM glycine pH 1.5. The wild type BMS-986325 was tested three separate times on each of the three independent flow cells for a total of 9 measurements. Data were analyzed using BIAcore™ T200 evaluation software by fitting to a 1:1 Langmuir model.
CD40 binding SPR: SPR studies of the purified antibodies were conducted on BIAcore™ T200 instrument (GE Healthcare, Chicago Ill.). A Series S Protein A sensor chip (GE Healthcare, Chicago Ill.) was equilibrated with SPR running buffer of 10 mM NaPO4, 130 mM NaCl, 0.05% tween 20, (PBS-T) pH 7.2 at 25° C. The purified antibody samples were diluted to 3 μg/ml in PBS-T and captured on the protein A surface for 30 s at 10 μl/min Binding of 3.91, 7.81, 15.6, 31.3, 62.5, and 125 nM human CD40 extracellular domain (produced in house) was evaluated using association time of 180 s at 30 μl/min, followed by a dissociation time of 360 s at 30 μl/min Regeneration between cycles was accomplished using two 15 s injections of 10 mM glycine pH 1.5. The wild type BMS-986325 was tested once on each of the three independent flow cells. Data were analyzed using BIAcore™ T200 evaluation software by fitting to a 1:1 Langmuir model.
aSEC analysis: Isocratic separations were performed on a Shodex™ K403-4F column (Showa Denko America, Inc., New York, N.Y.) connected to an Agilent 1260 series HPLC system in buffer containing 100 mM Sodium Phosphate, 150 mM Sodium Chloride pH 7.3 (0.1 μm filtered) running at 0.3 mL/min Injections of 20 μg of antibody were performed using an Agilent autosampler, and data were obtained using an Agilent diode array detector reading at 280 nm, 260 nm, 214 nm, 254 nm, with reference subtraction at 360 nm. Data were analyzed using Chemstation (Agilent) software.
icIEF analysis: Imaged capillary isoelectric focusing (icIEF) experiments were performed on a Maurice instrument (ProteinSimple, San Jose, Calif.). Instrument settings include pre-focus for 1 mM at 1500V and focus for 10 mM at 3000V. Antibody samples were first diluted to a final concentration of 2 mg/mL in double distilled water (ddH2O). In the final plate, 20 μL of sample were mixed with 180 μL of Master Mix (MM) for final concentrations of 0.35% methyl cellulose (MC), 2.0 M Urea, 1% v/v % Pharmalyte® 5-8, and 3% v/v % Pharmalyte® 8-10.5. MM contains per sample: 1.0% MC solution (70 μL), Pharmalyte® 5-8 (2 μL), Pharmalyte® 8-10.5 (6 μL), 8 M Urea (50 μL), Arginine (100×), dd Water (50 μL), pI marker 5.85 (1 μL), and pI market 10.10 (1 μL) (Pharmalyte®, Cytiva, Marlborough, Mass.). Data was obtained and analyzed using Compass for iCE by ProteinSimple.
aHIC analysis: The high-performance analytical hydrophobic interaction chromatography (aHIC) method was performed on a Agilent 1260 series HPLC. The data were collected at 280 nm, with reference subtraction at 360 nm. A Tosoh TSKgel Butyl NPR column with the dimensions 4.6 mm*3.5 cm, 2.5 μm particle size and flow rate of 1 mL/min was utilized for separation. A 20-minute linear gradient ranging from 1.8 M to 0.0 M Ammonium Sulfate in 0.1 M Sodium Phosphate buffer (pH 7.0). The column and auto sampler temperatures were set at 25° C. and 4° C., respectively. The column loading was 10 μg. Data were analyzed using Chemstation (Agilent) software.
Thermal stability analysis: Determination of the temperature of melting on-set and the temperature of aggregation on-set were performed utilizing an UNcle instrument (Unchained Labs). In brief, 9 μL of sample at 1 mg/mL were loaded into sample Uni cuvette, sealed, and placed into the instrument. A temperature gradient from 25° C. to 90° C. at 0.5° C./min was applied to the sample. Full-spectrum UV absorbance (250 nm-725 nm) as well as static light scattering emission at 266 nm and 473 nm specifically was obtained at each time-point. Fitting of resulting Tm/Tagg was performed by UNCLE analysis software (Unchained Labs).
ECM binding ELISA analysis: Extracellular matrix (ECM) binding ELISA assays were performed using 96 well Corning® Thin-Layer Matrigel® Matrix pre-coated ECM plates (Corning Incorporations Life Sciences, Tewksbury, Mass.). Plates were incubated for one hour at room temperature with 300 μl of blocking buffer (10% fetal calf serum (FCS) in TBS). After incubation 100 μl of fresh blocking buffer was added with 1 μM, 0.33 μM and 0.11 μM of antibody samples. Six wells had no sample addition for background and ECM score calculations. After one hour of sample incubation, samples were removed and plates washed with PBS-T wash buffer 3×. 10 ng/ml of goat anti-human IgG—HRP (horseradish peroxidase) conjugated detection antibody was added at 100 μl to all wells. After another one hour incubation at room temperature, the wells were washed 3× with PBS-T wash buffer. After washing, 100 μl of TMB (3,3′,5,5′-metramethylbenzidine) substrate was added to each well and allowed to react for 15 minutes, followed by addition of 100 μl of 1 M phosphoric acid stop solution. Absorbance was then read on a microplate reader at 450 nm referenced at 620 nm.
In vitro activity assessment of BMS-986325 and its variants in human B cell assays: Briefly, human tonsillar B cells were obtained from pediatric patients during routine tonsillectomy. After gently mashing the tissue, mononuclear cells were separated by density gradient separation using Lympholyte®-H separation media (Cedarlane Labs, Burlington, ON, Canada), washed, and rosetted with sheep red blood cells (SRBC, Colorado Serum Company; Denver, Colo.), followed by density gradient separation to remove T cells. Cells were washed and re-suspended in complete media consisting of RPMI-1640 with 2 mM L-Glutamine (Cat. #11875) supplemented with 10% fetal bovine serum (cat. #26140), 50 μg/ml gentamicin (cat. #15750) and 1% antibiotic-antimycotic (cat. #15240) (all purchased from Gibco; Carlsbad, Calif.).
Inhibition of soluble or membrane-bound CD40L stimulated Human B cell proliferation: Isoleucine zipper human CD40L trimer (IZ-hCD40L) or Chinese hamster ovary cells stably transfected with human CD40L (CHO-hCD40L) were used as a stimulus for CD40 activation and a positive control. CD40 agonist mAb2141-hHCD-IgG2-puCOEgate-SP5 was used as positive control for CD40 pathway activation by an agonist antibody. BMS-986325 antibodies were titrated in complete media and pipetted in triplicate to 96 well round bottom plates. 1×105 tonsillar B cells were added, and stimulated with either soluble IZ-hCD40L (3 μg/ml), or with CHO-hCD40L irradiated with 10,000 rads, and plated at 2×103 cells/well, in a final volume of 200 μl per well. Plates were incubated at 37° C. in a humidified incubator with 5% CO2 for 72 hours. During the last 7 hours of incubation, cells were labeled with 0.5 μCi of [methyl-3H]-thymidine per well, harvested on glass fiber filter plates, and counted by liquid scintillation on a Packard Topcount® NXT™ counter (PerkinElmer Life and Analytical Sciences, Shelton, Conn.). B cell proliferation was quantitated based on thymidine incorporation. For analysis, a 4-parameter curve was generated from triplicate values and fit using GraphPad Prism software (ver. 7, GraphPad Software, San Diego, Calif.).
Evaluation of potential agonism on human B cells with BMS-986325 and BMS-986325 variants: BMS-986325 and variant antibodies were titrated in complete media and pipetted in duplicate to 96 well round bottom plates. 2×105 tonsillar B cells were added, and stimulated with soluble hIL-4 (20 ng/ml, PeproTech, Inc.), antibody alone, or antibody plus IL-4 and soluble IZ-hCD40L (3 μg/ml). Plates were incubated at 37° C. in a humidified incubator with 5% CO2 for 72 hours.
Media was sampled at 48 hours for IL-6 measurement by AlphaLisa® (cat. #AL3025C, Perkin Elmer; Waltham, Mass.) according to the manufacturer's instructions and read on the EnVision® 2105 multimode plate reader (Perkin Elmer; Waltham, Mass.). For IL-6 production, greater than 2-fold induction over control was considered to be a positive indication of agonism.
During the last 7 hours of incubation, cells were labeled with 0.5 μCi of [methyl-3H]-thymidine (Perkin Elmer, Waltham, Mass.) per well, harvested on glass fiber filter plates, and counted by liquid scintillation on a Packard Topcount® NXT™ counter (Perkin Elmer, Waltham, Mass.). B cell proliferation was quantitated based on thymidine incorporation. For analysis, duplicate values were averaged and quantitated using GraphPad Prism software (ver. 7, GraphPad Software, San Diego, Calif.). Greater than 2-fold induction over control, unstimulated, or IL-4 alone, was considered to be positive for agonism.
Single-dose pharmacokinetic study in C57BL/6 mice after 1 mg/kg intravenous administration of BMS-986325 and its variants: As neither BMS-986325 nor its variants crossreact to murine CD40, the PK thus collected was “intrinsic PK” of the antibody without any impact of target mediated drug disposition (TMDD), typical in anti-CD40 antibodies. Briefly, 1 mg/kg antibody in phosphate buffer saline (PBS) was administered intravenously (IV) in C57/BL6 mice and 10 μL whole-blood was collected in tubes containing 90 μL of Rexxip® A Buffer (Gyros Protein Technologies, Tucson, Ariz.) over time for 6 weeks. The tubes, after being thoroughly mixed, were frozen until bioanalysis.
Analysis of BMS-986325 and its variants in mice micro-samples by Gyros immunoassay: After thawing, the blood samples were centrifuged and supernatants were analyzed for antibody using a qualified automated, microfluidic fluorescence immunoassay on the Gyrolab® xP Workstation (Gyros Protein Technologies, Tucson, Ariz.). Briefly, biotinylated huCD40-mouse IgG2b at 100 μg/ml was used as a capture molecule for the “active/free” antibody. Samples were analyzed at 10% minimum required dilution in 1% BSA/PBS/0.05% Tween®20 (PTB; Croda International, Edison, N.J.). Standard, QC, and study samples were brought up to a final matrix concentration of 10% mouse blood in Rexxip® A Buffer and loaded onto Gyrolab. The three-step Wizard method with Gyrolab® Bioaffy 200 CD was used. After final wash steps, the captured “active/free” antibody was detected using Alexa 64-labeled monkey anti-human IgG Fc mAb clone 1628.3379.1007.D12. The concentrations of antibody (“active/free”) in blood samples were calculated based on the corresponding fluorescence intensity as measured by Gyrolab using a 4PL (parameter logistic) regression standard calibration curve. Assay performance was within the acceptable range with % CV of the standards and QCs being below 20%, and QC recovery within ±20% of the nominal values.
These data are consistent with the hypothesis that the specific site or location of a mutation to modify a surface charge patch rather than just modifying the total antibody charge, is critical to improving antibody PK. For example, variants with 1 or 2 strategically placed mutations and less change in overall charge of −2 (M33) or −3 (M47) have equivalent or better PK compared to a mutant with 6 mutations and larger change in charge of −8 (M53).
Although the present embodiments have been described in detail with reference to examples above, it is understood that various modifications can be made without departing from the spirit of these embodiments, and would readily be known to the skilled artisan.
These and other aspects disclosed herein, including the exemplary specific treatment methods, medicaments, and uses listed herein, will be apparent from the teachings contained herein.
This application claims the benefit of U.S. Provisional Application No. 63/026,499, filed May 18, 2020, which is hereby incorporated in its entirety for all purposes.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2021/032815 | 5/17/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63026499 | May 2020 | US |
